bims-fagtap Biomed News
on Phage therapies and applications
Issue of 2026–11–01
78 papers selected by
Luca Bolliger, lxBio



  1. Mol Biol Rep. 2026 Oct 30. pii: 1864. [Epub ahead of print]53(1):
      Mixed-species biofilm infections are important causes of persistent and difficult-to-treat infections. Compared with monospecies biofilms, mixed-species communities contain microorganisms with different physiological and genetic characteristics that interact through metabolic cooperation, chemical signaling, competition, and modification of the local environment. These interactions, together with the EPS matrix, physiological heterogeneity, and HGT, can increase antimicrobial tolerance, contributing to treatment failure and infection recurrence. Polymicrobial biofilms are associated with chronic wounds, respiratory infections, catheter- and device-associated infections, and other persistent infections. However, treatment of polymicrobial biofilms remains challenging because their complex structure and interspecies interactions can reduce antimicrobial efficacy. This review summarizes the clinical significance, formation, and persistence of mixed-species biofilms and discusses recent therapeutic strategies for their control. We also discuss recent approaches for controlling polymicrobial biofilms, including natural compounds, QS inhibition, CRISPR-Cas-based approaches, biofilm matrix targeting, metabolic and nutrient disruption, nanotechnology, and phage therapy. Recent studies show that these approaches can inhibit biofilm formation, disrupt established biofilms, enhance antimicrobial activity, and selectively target specific microbial populations. However, their effectiveness varies with microbial composition, biofilm maturity, matrix characteristics, and treatment conditions. Overall, current evidence supports the development of targeted and combination-based strategies for mixed-species biofilms. Further studies using clinically relevant models are needed to exactly define treatment efficacy and support the translation of these approaches into clinical practice.
    Keywords:  CRISPR-Cas System; Nanotechnology; Natural Compound; Phage Therapy; Polymicrobial Biofilm; Quorum Sensing System
    DOI:  https://doi.org/10.1007/s11033-026-12907-3
  2. Viruses. 2026 Sep 22. pii: 1050. [Epub ahead of print]18(10):
      Cystic fibrosis (CF) is an autosomal recessive genetic disorder that disrupts ion transport across epithelial surfaces, impairing mucociliary clearance and predisposing patients to chronic, often refractory bacterial infections. At the Eliava Phage Therapy Center (EPTC) in Tbilisi, Georgia, we utilize bacteriophage preparations to treat chronic pulmonary infections caused by various bacterial pathogens, including Staphylococcus aureus, Pseudomonas aeruginosa, Achromobacter xylosoxidans, and Burkholderia cepacia. This case report describes the successful treatment of a CF-related infection in a male patient with a ΔF508 mutation using Pyophage and Intestiphage preparations, as well as customized phages developed against specific P. aeruginosa isolates. The efficacy of phage therapy was assessed by evaluating clinical improvement, pulmonary function, inflammatory markers, and bacterial burden. We observed improvement across all assessed parameters, including a complete eradication of P. aeruginosa in sputum culture tests. This case highlights the potential of phage therapy as a primary antimicrobial approach for the long-term management of pulmonary infections in patients with CF.
    Keywords:  antibiotic-resistance; bacteriophage therapy; cystic fibrosis
    DOI:  https://doi.org/10.3390/v18101050
  3. Trends Microbiol. 2026 Oct 28. pii: S0966-842X(26)00280-5. [Epub ahead of print]
      Antimicrobial resistance poses a critical global health threat, and renewed interest in bacteriophage (phage) therapy highlights its potential as a targeted alternative to antibiotic monotherapy. However, phage resistance in bacteria remains a key limiting factor in phage therapy, driven by evolutionary adaptations to phage exposure. Antibacterial modalities (antibiotics, adjuvants, antimicrobial peptides, and RNA-based therapeutics) could help overcome these barriers and represent untapped potential for synergistic, precision antimicrobial interventions when combined with phage therapy. Importantly, bacterial physiology and environmental context could strongly influence treatment outcomes, underscoring the need for clinically relevant models for testing combinations. Integration of multi-omics and artificial intelligence-driven approaches could help predict patterns for the development of precision therapies and support the development of novel antimicrobial interventions.
    Keywords:  antibacterial modalities; antimicrobial resistance; bacteriophage therapy; next-generation combination phage therapeutics
    DOI:  https://doi.org/10.1016/j.tim.2026.10.001
  4. JCI Insight. 2026 Oct 27. pii: e209406. [Epub ahead of print]
      The increase in antimicrobial resistant infections has fueled a resurgent interest in bacteriophage (phage) therapy. We conducted a literature review of personalized phage therapy cases in the peer-reviewed, English-language literature reported between 1/1/2005, to 8/31/2025 for which individual patient data were available, identifying and synthesizing data from a total of 323 patients described in 83 studies. Most patients (68%, 221/323) were treated with ≥ 2 phages (a phage cocktail). The median concentration of phages was 108 PFU/mL (IQR 107-109). Most patients (76%, 246/323) received antibiotics concurrent with phage therapy. The median duration of therapy was 10 days (IQR 5-21). The most common indications for phage therapy were skin/soft tissue, pulmonary, orthopedic, osteoarticular, and genitourinary infections. 144 patients received fixed (off-the-shelf) phage preparations whereas 179 received bespoke phage preparations (i.e., personalized therapy). For cases where outcomes data were available, 78% (253/323), experienced clinical improvement while the targeted pathogen was eradicated in 61% (177/290) of cases. Nine patients had treatment withdrawn due to tolerability concerns. These data indicate that there is substantial heterogeneity in current personalized phage therapy clinical practices but that this approach can be successful.
    Keywords:  Bacterial infections; Infectious disease; Virology
    DOI:  https://doi.org/10.1172/jci.insight.209406
  5. Future Microbiol. 2026 Oct 29. 1-15
      The worldwide emergence of antimicrobial resistance and the need for non-conventional alternatives to conventional antibiotics have been increased by multidrug-resistant ESKAPE pathogens, which cause the majority of nosocomial infections and are starting to develop resistance to even the most potent drugs. Engineered bacteriophages are promising precision antimicrobials because of their ability to selectively infect and lyse bacterial hosts, multiply at infection sites, and co-evolve with bacterial populations to overcome resistance. Advances in synthetic biology, such as tail fiber modification, depolymerase and endolysin enhancement, genome editing using the clustered regularly interspaced short palindromic repeats (CRISPR), and computationally designed phage cocktails, have opened new possibilities for therapeutics that were hindered by the limitations of natural phages. These engineering strategies expand host range, enhance biofilm penetration, and target resistance genes. In spite of promising evidence in preclinical models, the use of engineered phages in routine clinical practice remains difficult. Specific key challenges include unclear regulations, lack of good manufacturing practice (GMP)grade production, variable pharmacokinetics and limited clinical trial data. This review critically examines engineering approaches to improve phage activity against ESKAPE pathogens, identifies the scientific and regulatory barriers limiting clinical use, and outlines the key steps needed for wider adoption.
    Keywords:  Antimicrobial resistance; ESKAPE pathogens; engineered bacteriophages; multidrug-resistant bacteria; phage therapy
    DOI:  https://doi.org/10.1080/17460913.2026.2752147
  6. Front Microbiol. 2026 ;17 1882663
      Diabetic foot ulcers (DFUs) are a major cause of hospitalization, chronic infection, and non-traumatic lower-limb amputation, imposing substantial clinical and economic burdens worldwide. Standard DFU management requires a multidisciplinary approach involving pressure offloading, regular debridement, infection control, metabolic optimisation, vascular assessment, and revascularisation when indicated. Offloading and sharp debridement reduce mechanical stress, remove devitalized tissue, disrupt biofilms, and support wound healing. Infected ulcers require appropriate microbiological assessment and culture-directed antimicrobial therapy, particularly when multidrug-resistant (MDR) pathogens are present. Biofilm formation is an important feature of chronic DFUs and is associated with persistent infection, delayed healing, and treatment failure. Biofilm-associated antimicrobial tolerance results from factors including reduced antimicrobial penetration, metabolic dormancy, altered growth states, and phenotypic heterogeneity, and should be distinguished from genetically mediated antimicrobial resistance caused by acquired or chromosomal genetic determinants. Although biofilm-associated tolerance does not necessarily involve genetic resistance, persistent biofilm infection may facilitate the selection and persistence of resistant subpopulations. Both Gram-positive and Gram-negative organisms can form biofilms in DFUs. Novel antibiotics, including oxazolidinones, lipoglycopeptides, lipopeptides, and advanced β-lactam/β-lactamase inhibitor combinations, may provide options for selected difficult to treat infections, although evidence varies among agents and clinical settings. Adjunctive wound-care strategies, including appropriate dressings and negative-pressure wound therapy, may support wound-bed preparation and healing in selected cases. Emerging approaches such as nanoparticle-based delivery systems, hydrogels, nanofibrous scaffolds, stem-cell and exosome therapies, gene and RNA-based strategies, and oxygen-releasing biomaterials have shown potential in preclinical and early clinical studies. However, their clinical effectiveness, safety, reproducibility, scalability, and regulatory approval and clinical translation remain incompletely established. Integrating evidence-based standard care with appropriate antimicrobial therapy and carefully evaluated emerging technologies may facilitate individualized management of complex DFUs.
    Keywords:  biofilm; diabetic foot ulcer; multidrug-resistant infections; nanotechnology-based drug delivery; wound healing therapies
    DOI:  https://doi.org/10.3389/fmicb.2026.1882663
  7. bioRxiv. 2026 Sep 04. pii: 2026.09.01.748673. [Epub ahead of print]
      The rise of antibiotic-resistant bacteria demands alternative therapeutic strategies, with bacteriophage (phage) therapy and phage-derived enzybiotics emerging as promising approaches. However, identifying candidate phages against specific pathogens has historically been a bottleneck due to the need for cultivation methods to assess host range and lytic activity. Advances in metagenomic sequencing and the emergence of large-scale viral genome databases now provide an opportunity to accelerate this process computationally. Here, we present a large-scale mining of the MetaVR database to identify phages targeting human bacterial pathogens. By integrating direct host associations with CRISPR-spacer evidence, we linked 196,472 high-quality and complete viral genomes, representing 42,360 vOTUs, to 618 species of pathogenic and opportunistic bacteria. Functional enrichment analysis revealed distinct genomic signatures with viral lifestyle and host-range breadth: virulent phages were enriched in replication and structural functions, whereas temperate and broad host-range phages were enriched in anti-defense and regulatory modules. To characterize their lytic potential we annotated lysis-related protein families and their structural diversity, identifying 76 structurally novel lysis-associated proteins, including candidates targeting WHO priority pathogens. Focused analysis of endolysins revealed 592 structural clusters, with extensive sharing of endolysin repertoires among ESKAPE pathogens, suggesting candidates for broad-spectrum enzybiotic development. Selection analysis identified 167 endolysin families with sites under positive selection within functional domains, highlighting evolutionary diversification potentially associated with phage-host interactions. Together, our results establish a large-scale framework for connecting human bacterial pathogens to phages and their lytic machinery, providing a resource for prioritizing phage therapy and enzybiotic development.
    Importance: Antibiotic resistance is a growing global health crisis, and phage therapy represents a promising alternative to conventional antibiotics. By leveraging a large-scale viral genomic database to computationally link almost 200,000 phage genomes to 618 human pathogen species, we substantially expand the catalog of known phage-pathogen interactions. Additionally, we characterize the lysis machinery encoded by these phages, including holins, spanins and endolysins uncovering structurally novel enzymes, associated with phages targeting WHO priority pathogens that could serve as starting points for enzybiotic development. We also reveal extensive sharing of endolysin repertoires among pathogen species, indicating opportunities for developing broad-spectrum enzybiotic strategies. By providing a systematic, genomics-driven framework for identifying and prioritizing phage-derived therapeutic candidates, this work translates large-scale viral genomic data into a resource for developing new therapeutic strategies against drug-resistant bacterial infections.
    DOI:  https://doi.org/10.64898/2026.09.01.748673
  8. Folia Microbiol (Praha). 2026 Oct 30.
      Bacterial infections continue to pose a significant health risk with CNS infections contributing to a huge death toll every year. Pathogens such as Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis are the prominent causes of these infections. Over the recent years, many of these bacteria have become resistant to antibiotics. Phage therapy can complement and supplement the traditional antibiotics as it employs bacteriophages to specifically target pathogenic bacteria. Phages reported in many research studies have been able to successfully target pathogens of the CNS. A number of pre-clinical studies have investigated the pharmacological effectiveness of phage therapy in CNS infections exhibiting adequate transport across the blood brain barrier. These findings have enhanced the confidence in the therapeutic potential of phages as they can inhibit bacterial infections, relieve inflammatory responses and subsequently, treat CNS infections. Phages and endolysins given systemically can be detected and measured in brain and CSF, but the extent of BBB crossing should be further investigated as it has limited direct evidence. However, today, owing to its targeted action, adequate tissue distribution and autodosing, phage therapy can serve as an ideal option for addressing hard-to-treat CNS infections caused by antibiotic resistant bacteria, despite of its challenging pharmacokinetics and formulation development. The current review presents the opportunities and challenges, in terms of pharmacological, therapeutic and regulatory aspects, with relevance to the incorporation of phage therapy in clinical settings for the treatment of CNS infections.
    Keywords:  Bacteriophage; Blood Brain Barrier; CNS Infections; Meningitis; Phage Therapy
    DOI:  https://doi.org/10.1007/s12223-026-01629-5
  9. Adv Wound Care (New Rochelle). 2026 Oct 27. 21621918261501846
       SIGNIFICANCE: Chronic wound infections, including diabetic foot infections, are increasingly recognized as biofilm-associated polymicrobial ecosystems rather than simple planktonic infections. However, routine microbiological workflows remain largely optimized for acute infections, creating a mismatch between laboratory diagnostics and the biological organization of chronic infection.
    RECENT ADVANCES: Growing evidence from biofilm biology, microbial ecology, and molecular microbiology has demonstrated that chronic wound infections are characterized by structured microbial communities, physiological heterogeneity, and enhanced antimicrobial tolerance. Advanced diagnostic approaches have improved understanding of microbial diversity and biofilm-associated persistence beyond what is captured by conventional culture alone.
    CRITICAL ISSUES: Conventional microbiological workflows may incompletely resolve the microbial populations most relevant to chronicity, recurrence, and treatment failure. Key limitations include sampling strategy, tissue processing, incubation conditions, anaerobic recovery, and reliance on planktonic susceptibility testing. The discrepancy between minimum inhibitory concentration-based testing and biofilm-associated antimicrobial tolerance highlights an important gap between laboratory assessment and infection biology.
    FUTURE DIRECTIONS: Modernization of chronic wound microbiology requires a transition from pathogen-centered planktonic models toward biofilm-aware, ecosystem-oriented approaches. Integration of optimized sampling, culture-based diagnostics, selective molecular tools, surgical source control, and antimicrobial stewardship may improve diagnostic resolution, support more rational antimicrobial use, and enhance long-term clinical outcomes.[Figure: see text].
    Keywords:  antimicrobial stewardship; biofilms; chronic wound infections; diabetic foot infections; microbiological diagnosis
    DOI:  https://doi.org/10.1177/21621918261501846
  10. J Appl Oral Sci. 2026 ;pii: S1678-77572026000101001. [Epub ahead of print]34 e20260384
      The oral microbiome is a natural and essential component of the human body, maintaining a symbiotic relationship with the host and contributing to health. Rather than being caused simply by the presence of microorganisms, oral diseases are now understood as ecological dysbioses, in which disruption of the oral microbiome precedes and drives the development of clinical signs. This perspective challenges traditional clinical approaches, as strategies focused exclusively on detecting or eliminating specific microorganisms are unlikely to address the ecological nature of oral diseases and may, in some cases, be counterproductive. Furthermore, far beyond local effects, oral dysbiosis may have systemic repercussions. Through mechanisms such as chronic inflammation and interactions along the oral-gut axis, oral dysbiosis may influence systemic health and has been associated with cardiovascular, metabolic, neurodegenerative, and autoimmune diseases. This relationship is bidirectional: oral dysbiosis may contribute to systemic inflammatory and metabolic alterations, while systemic conditions can also modify the oral environment. As oral microbiome discoveries increasingly reach dental professionals, there is a growing need to critically translate this body of evidence into clinically meaningful concepts. This review aims to help bridge the gap between rapidly evolving oral microbiome research and everyday dental practice by providing dental professionals with an integrated ecological perspective of the oral microbiome. By synthesizing emerging concepts in microbiome homeostasis, dysbiosis, resilience, and oral-systemic interactions into clinically relevant principles, this review can support evidence-based decision-making in contemporary dentistry. The role of dental professionals in maintaining oral microbiome balance is part of a broader strategy to support both oral and systemic health. Recognizing oral diseases as ecological dysbiosis highlights the need for a shift in dental practice, in which preserving microbiome eubiosis and ecological stability becomes central to care. In dysbiosis, the microbiome becomes an enemy, so it is better kept on our side.
    DOI:  https://doi.org/10.1590/1678-7765-2026-0384
  11. Front Cell Infect Microbiol. 2026 ;16 1942138
      Periodontitis is one of the most prevalent chronic inflammatory diseases in the oral cavity, characterized by progressive destruction of periodontal supporting tissues. Its pathogenesis involves complex interactions between the oral microbiota and host immune responses. This condition not only severely impacts oral health but is also closely associated with multiple systemic diseases. In recent years, the link between periodontitis and systemic lupus erythematosus (SLE) has garnered increasing attention. This review examines the compositional characteristics of the oral microbiota in patients with SLE and the epidemiological evidence linking periodontitis to SLE. It focuses on how periodontitis may trigger or exacerbate SLE's autoimmune responses through the oral microbiota, via mechanisms such as molecular mimicry, cytokine-mediated immune activation, and microbial translocation, while elucidating the underlying pathophysiological and immunological mechanisms. Furthermore, this paper aims to explore potential prevention and treatment strategies based on oral microbial interventions, to provide novel insights and theoretical foundations for adjunctive therapy and disease management in SLE.
    Keywords:  autoimmune; dysbiosis; oral microbiota; periodontitis; systemic lupus erythematosus
    DOI:  https://doi.org/10.3389/fcimb.2026.1942138
  12. Clin Dermatol. 2026 Oct 28. pii: S0738-081X(26)00306-8. [Epub ahead of print]
      Diabetic foot ulcers (DFUs) are a major complication of diabetes and are associated with impaired healing, lower-extremity amputation, and substantial morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in the management of type 2 diabetes and obesity, with emerging evidence suggesting potential effects on diabetic foot health beyond glycemic control. This review examines the mechanistic and clinical evidence linking GLP-1RA therapy to DFU development, healing, and lower-extremity outcomes. Experimental studies demonstrate anti-inflammatory and antioxidant effects, improved endothelial function and angiogenesis, enhanced cellular repair, and potential neuroprotective effects. Clinical studies further suggest favorable associations with incident DFU, lower-extremity amputation, wound-related complications, and mortality, although findings are not uniform and most evidence is observational. Emerging data also suggest potentially favorable postoperative outcomes in patients undergoing diabetic foot and lower-extremity procedures. Comparative studies across glucose-lowering therapies demonstrate heterogeneous findings and do not establish a consistent advantage of one drug class across diabetic foot outcomes. Substantial GLP-1RA-associated weight loss may be accompanied by reductions in lean mass and nutritional intake and may raise additional concerns regarding peripheral neuropathy, wound healing, and foot biomechanics. However, direct evidence linking GLP-1RAs to plantar fat-pad loss, altered plantar pressure, or impaired DFU healing is lacking. Overall, GLP-1RAs may offer benefits relevant to diabetic foot health, but prospective studies using validated wound-healing endpoints are needed to determine whether these therapies directly improve DFU healing and to clarify their role in diabetic foot management.
    Keywords:  GLP-1; SGLT2 inhibitor; amputation; angiogenesis; diabetic foot ulcer; peripheral neuropathy; wound healing
    DOI:  https://doi.org/10.1016/j.clindermatol.2026.10.010
  13. Front Microbiol. 2026 ;17 1953496
       Introduction: The escalating antimicrobial resistance in Klebsiella pneumoniae underscores the urgent need for alternative therapies. Phage therapy represents a promising approach owing to its specificity, phage self-replication, and potential synergy with antibiotics. Yet, the narrow host range of phages and rapid emergence of resistance necessitate the discovery of novel phages with diverse specificities, which can be facilitated by screening geographically distant environmental reservoirs. Here, we describe four novel Klebsiella bacteriophages belonging to the subfamily Studiervirinae, isolated from hospital wastewater in Mumbai, India. We characterized their host range, infection kinetics, physicochemical stability, complete genome sequences, phylogenetic placement, and encoded depolymerases to evaluate their potential as candidates for precision phage therapy against K. pneumoniae.
    Methods: Phages were isolated via enrichment on clinical K. pneumoniae and sequenced using a hybrid approach. Following genomic annotation and in silico depolymerase prediction, phages were characterized by transmission electron microscopy, one-step growth curves, and thermal/pH tolerance assays. The capsular specificity of native phages and recombinant depolymerases was evaluated via spot assays against 198 clinical K. pneumoniae isolates.
    Results: The four phages were classified as novel species within the subfamily Studiervirinae (genera Przondovirus and Teetrevirus), exhibiting strictly lytic lifestyles and favorable safety profiles devoid of antimicrobial resistance genes. They demonstrated strict specificity for clinically prominent capsular types (KL2, KL22, KL25, KL35, and KL47), with phage 1627 uniquely displaying dual specificity for both KL2 and KL22. All phages showed robust stability across broad pH (4-11) and temperature (4-50 °C) ranges. Expression of the recombinant depolymerase yielded preliminary evidence of targeted capsular degradation via spot assays, supporting in silico structural predictions of potential in vitro lytic activity.
    Discussion: These findings suggest that cross-regional environmental screening is a promising strategy for identifying phages effective against local multidrug-resistant clinical pathogens. Moreover, these newly described phage species and their putative depolymerases represent a promising addition to the expanding therapeutic arsenal against K. pneumoniae infections.
    Keywords:  Klebsiella pneumoniae; Przondovirus; Teetrevirus; bacteriophage; depolymerase; genome; novel species; phage therapy
    DOI:  https://doi.org/10.3389/fmicb.2026.1953496
  14. Front Microbiol. 2026 ;17 1953464
      Periodontitis is a common oral inflammatory disease characterized by chronic inflammation and progressive destruction of the tooth-supporting tissues. Its initiation and progression are not driven solely by infection with specific periodontal pathogens, but rather arise from complex interactions among oral microbial dysbiosis, dysregulated host immune responses, and tissue remodeling. In recent years, oral microbiota-immune crosstalk has emerged as a central mechanistic link between microbial dysbiosis and periodontal tissue damage. Accumulating evidence indicates that oral microorganisms can modulate both innate and adaptive immune responses through microbial structural components, biofilm-associated factors, and metabolites. Conversely, persistent immune-inflammatory responses may reshape the composition and function of the oral microbiota by disrupting barrier integrity, altering the local metabolic milieu, and remodeling ecological niches, thereby establishing a potential self-reinforcing feedback loop. This review focuses on oral microbiota-immune crosstalk in periodontitis, summarizing the molecular mechanisms through which the microbiota regulates host immunity and, reciprocally, immune responses reshape the microbial ecosystem. Particular emphasis is placed on the dynamic changes in these interactions across disease-associated states, including inflammatory initiation, maintenance of chronic inflammation, periodontal tissue destruction, and establishment of a disease-associated microbial ecosystem. We further review the therapeutic and translational advances targeting the microbiota-immune network, including conventional periodontal therapy, biofilm modulation, probiotics, prebiotics and dietary interventions, adjunctive antimicrobial therapy, bacteriophage-based approaches, and engineered bacteria. Finally, we discuss future directions involving multi-omics integration, precision microbiota modulation, and individualized therapeutic strategies, with the aim of providing a conceptual framework and new avenues for the precision prevention and treatment of periodontitis and for the development of microbiota-immune-targeted therapies.
    Keywords:  disease progression; microbial dysbiosis; microbiota-immune crosstalk; oral microbiota; periodontitis; precision therapy
    DOI:  https://doi.org/10.3389/fmicb.2026.1953464
  15. Dent J (Basel). 2026 Oct 01. pii: 625. [Epub ahead of print]14(10):
      The oral cavity is a continuous microbial source for the gastrointestinal tract. Adults swallow approximately 0.5-1.5 L of saliva each day, carrying a large and variable bacterial load. Gastric acidity removes most ingested organisms, but survival increases with food buffering, acid tolerance, mucin or biofilm protection, and proton-pump inhibitor use. Oral taxa are therefore repeatedly detected in stool, intestinal mucosa, and diseased tissues. The strongest mechanistic evidence concerns Fusobacterium nucleatum in colorectal cancer and Porphyromonas gingivalis in inflammatory and metabolic pathways, although detection alone does not prove stable colonization or causality. This narrative review summarizes microbial transit, key taxa, salivaomics, systemic associations, and practical oral control points. It also identifies clinical control points, including probiotics and polyols such as xylitol, as selective microbiome-modulating adjuncts at varying stages of evidence. The evidence suggests a strong clinical message: treat oral dysbiosis for established dental reasons, while paired oral and gut studies determine when downstream systemic benefits are achieved.
    Keywords:  Fusobacterium nucleatum; Porphyromonas gingivalis; colorectal cancer; ectopic oral bacteria; gastric transit; gut microbiome; oral microbiome; periodontal disease; salivaomics; xylitol
    DOI:  https://doi.org/10.3390/dj14100625
  16. Int J Mol Sci. 2026 Oct 13. pii: 9060. [Epub ahead of print]27(20):
      Periodontitis is a chronic inflammatory disease associated with subgingival dysbiosis and altered host response. Although it is usually considered a local disease of the tooth-supporting tissues, it may also interact with distant mucosal and systemic compartments. One possible explanation is the oral-gut-systemic axis. In this model, oral bacteria, microbial products and inflammatory mediators are swallowed and reach the gastrointestinal tract. In susceptible hosts, these signals may affect gut microbial ecology, epithelial barrier integrity, mucosal immunity and microbial metabolite pathways. Human studies show links between periodontitis, altered oral and gut microbial communities, oral-gut microbial signatures and systemic metabolomic changes. Experimental studies provide stronger mechanistic support. They suggest that periodontal pathogens, particularly Porphyromonas gingivalis, may promote gut dysbiosis, barrier dysfunction, endotoxemia, inflammasome activation, T helper 17/regulatory T cell (Th17/Treg) imbalance and changes in metabolite signaling pathways. Candidate pathways include aryl hydrocarbon receptor (AHR) signaling, suppression of G protein-coupled receptor 109A (GPR109A), short-chain fatty acid-related pathways and trimethylamine N-oxide (TMAO) metabolism. Inflammatory bowel disease is currently the most developed disease-specific model. Metabolic dysfunction-associated steatotic liver disease (MASLD), non-alcoholic fatty liver disease (NAFLD), rheumatoid arthritis, cardiometabolic metabolite pathways and gastrointestinal cancer models are less mature extensions. This review summarizes current evidence and identifies the need for longitudinal studies, strain-level source tracking, multi-omics, immune phenotyping and disease-specific intervention studies. At present, the concept is biologically plausible, but clinical translation remains premature.
    Keywords:  MASLD; NAFLD; gut microbiome; immune crosstalk; inflammatory bowel disease; intestinal barrier; microbial metabolites; oral microbiota; oral–gut axis; periodontal dysbiosis; periodontitis; salivary microbiota
    DOI:  https://doi.org/10.3390/ijms27209060
  17. Clin Liver Dis. 2026 Nov;pii: S1089-3261(26)00070-X. [Epub ahead of print]30(4): 863-882
      Cystic Fibrosis-associated Hepatobiliary involvement (CFHBI) refers to a wide range of liver and biliary-related clinical and/or biochemical abnormalities that impact people with cystic fibrosis. Advanced cystic fibrosis liver disease (aCFLD) describes individuals with advanced fibrosis or cirrhosis and/or portal hypertension. The current review discusses both CFHBI and aCFLD in terms of pathogenesis; clinical, imaging and biochemical manifestations; screening, monitoring, and management recommendations; and the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy.
    Keywords:  CFTR modulator therapy; Cirrhosis; Cystic fibrosis; Hepatobiliary; Liver; Portal hypertension
    DOI:  https://doi.org/10.1016/j.cld.2026.07.008
  18. Dent J (Basel). 2026 Sep 23. pii: 617. [Epub ahead of print]14(10):
      Background/Objectives: The aim of this systematic review was to synthesise evidence on how non-surgical periodontal therapy (NSPT) alters the oral microbiota and periodontal parameters in patients with diabetes and periodontitis compared with non-diabetic patients with periodontitis. Methods: Electronic searches of MEDLINE/PubMed, Scopus, Embase, Ovid Emcare, JBI EBP, Web of Science, Dentistry and Oral Sciences Source, and grey literature sources were conducted from inception to March 2025. Eligible studies were clinical studies that included participants with diabetes and periodontitis, used NSPT as the primary intervention, and reported pre- and post-treatment oral microbiological and periodontal parameters as outcomes. The risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomised trials, and ROBINS-I for non-randomised studies and certainty of evidence was evaluated with GRADE. The review protocol was registered with PROSPERO (CRD420251005668). Results: Fourteen studies involving 374 participants with diabetes and 276 non-diabetic participants with periodontitis were eligible for inclusion. Thirteen studies used targeted methods restricted to pre-specified taxa, and one used 16S rRNA gene sequencing. In the targeted studies, NSPT was associated with reductions in periodontal pathogens, particularly Porphyromonas gingivalis, Tannerella forsythia, and Aggregatibacter actinomycetemcomitans, which were found in both diabetic and non-diabetic groups, with small or no differences observed between the groups. There were improvements in probing depth, clinical attachment, bleeding on probing and plaque scores after NSPT in both groups, with no consistent between-group differences. In most studies, RoB 2 was rated "some concerns", and GRADE ranged from very low to moderate for microbiological and clinical outcomes. Conclusion: NSPT reduces selected periodontal pathogens and improves periodontal parameters in adults with periodontitis, with and without diabetes. Community-level microbiome evidence is limited to one small study, and the available data do not show whether diabetes modifies the microbiological response to NSPT.
    Keywords:  diabetes mellitus; microbiome; periodontal attachment loss; periodontal debridement; periodontal pocket; periodontitis
    DOI:  https://doi.org/10.3390/dj14100617
  19. Ir Med J. 2026 Oct 22. 119(9): 172
       Aim: Up to 34% of diabetic patients will develop diabetic foot ulcers (DFUs) over their lifetime, with significant associated morbidity, mortality, and healthcare costs. Timely access to a multidisciplinary foot team (MDFT) can reduce DFU complications and represents the gold standard of management. Despite this, MDFT in Ireland is perceived to be ad hoc. This short report presents feedback from Irish healthcare professionals working on the frontline of diabetic foot disease.
    Methods: An opportunistic electronic mixed-method surveys was sent to all attendees of the Beaumont Multidisciplinary Diabetic Foot Care Symposium, a cross-speciality meeting of stakeholders in diabetic foot care across hospital and community settings in Ireland. A series of categorial and Likert scale questions were designed to gather current perspectives on service design and delivery. A thematic analysis was performed on free-text responses.
    Results: The response rate was 84/160 (52%), including 35 podiatrists (42%), 30 doctors (36%), 14 nurses (17%) and 3 orthotists (3.5%). Based on meeting content, 79/84 (94%) of responders reported they found the meeting "relevant or very relevant" to their current practice and 60/84 (71%) reported they were "likely or very likely" to change their practice. 73/77 (95%) of responders were in favour of a designated "Diabetic Foot Coordinator" to bridge community and hospital care. A thematic analysis of free-text "key take-aways" identified the importance of a formalised multidisciplinary DFU service with "buy-in" from all specialties as the most common response (58 [69%]).
    Discussion: Regular multidisciplinary meetings can showcase gold-standard care, update on current developments towards MDFT in Ireland and facilitate networking between specialties. However, institutional support, ring-fenced funding and realistic key performance indicators are needed to advance Irish diabetic foot care in line with international best practice.
  20. Ther Adv Respir Dis. 2026 Jan-Dec;20:20 17534666261493710
      Widespread availability of cystic fibrosis transmembrane conductance regulator modulator therapy (CFTRm) has resulted in improved health and quality of life for many people with cystic fibrosis (CF) and a subsequent rise in pregnancies among females with CF (FwCF). An increasing number of pregnancies are now occurring in women who are chronically infected with clinically significant respiratory pathogens, in particular the Burkholderia cepacia complex (BCC) and non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABC). These pathogens are associated with accelerated pulmonary decline, multi-drug antimicrobial resistance patterns and complex, prolonged treatment regimens making them important considerations in pregnancy management. Historically, chronic BCC infection has been linked to poorer obstetric and perinatal outcomes in FwCF, although much of the available evidence predates the CFTRm era and may not reflect the current clinical landscape. Similarly, while NTM infection, most significantly MABC, remains a major clinical challenge and contraindication for lung transplantation in people with cystic fibrosis (PwCF), there is a paucity of published data describing pregnancy outcomes in FwCF living with chronic NTM infection. As CFTRm has shifted disease trajectories and expanded reproductive possibilities, updated evidence describing risks and outcomes is urgently needed. This case series addresses this gap by examining CF-specific, obstetric, and neonatal outcomes in ten pregnancies: four in FwCF chronically infected with BCC and six with NTM infection. All pregnancies ended in live births: nine infants born at term, and one at 32+5 weeks from spontaneous premature labour, requiring the only admission to neonatal intensive care. CFTRm were used in nine pregnancies, and admission to hospital was required in two pregnancies for infective exacerbations of CF. There were no maternal deaths and no maternal intensive care admissions. These findings contribute essential new insights to guide counselling, risk assessment, and multidisciplinary management for pregnant FwCF with chronic infection by these high-risk pathogens.
    Keywords:  Burkholderia cenocepacia complex; CFTR modulator; Non-tuberculous mycobacteria; case series; cystic fibrosis; pregnancy; pregnancy in cystic fibrosis
    DOI:  https://doi.org/10.1177/17534666261493710
  21. Int Wound J. 2026 Nov;pii: e71077. [Epub ahead of print]23(11):
      Diabetic foot ulcer (DFU) is a common complication of diabetes in low- and middle-income countries and may be complicated by gas gangrene (GG), a rapidly progressive, life-threatening infection. This prospective study assessed whether GG can be diagnosed clinically in low-resource primary care and explored factors associated with wound-healing outcomes in DFU complicated by GG. From December 2021 to June 2025, consecutive patients with diabetic foot infection and clinically active GG were enrolled. Data included demographics, ulcer history and examination, SINBAD classification, GG signs, sepsis status, comorbidities, management, and outcomes. All participants had classical clinical features of GG and were admitted for urgent surgical treatment. Ninety-nine patients (58 male) with classical GG were admitted for urgent surgery. Initial amputation was required in 18% (major 12%, minor 6%). Ten patients were lost to follow-up; that included six who died from foot-ulcer-related causes. Of 89 followed, 30 (33.7%) healed in 225.5 ± 126.9 days, while 59 remained unhealed after 146.1 ± 175.4 days; major amputations during treatment were more frequent in the healed group. Having a previous history of ulcer showed to increase the time to heal by 136 days. A one-day increase in treatment duration was associated with a 1% decrease in both the chance of healing or risk of amputation. Early diagnosis, aggressive medical and surgical intervention are the keys to decreasing morbidity and mortality of diabetic patients with gas gangrene; and remain the mainstay treatment of this dangerous condition globally. Patient's with previous ulcer history were found to need longer time to heal. Increasing treatment duration seems to be a double-edged sword, as while it is associated with reduced risk of amputation, it also decreases the chance of ulcer healing.
    Keywords:  amputation; diabetes; diabetic foot; foot ulcer; gas gangrene; infection
    DOI:  https://doi.org/10.1111/iwj.71077
  22. Front Endocrinol (Lausanne). 2026 ;17 1926211
       Background: Diabetic foot infection, particularly with multidrug-resistant organisms (MDROs), is a serious complication of diabetic foot ulcers (DFUs) that increases wound healing time and amputation risk. Prolonged use of broad-spectrum antibiotics can contribute to antibiotic resistance and limit future treatment options. Developing effective non-antibiotic antibacterial therapies is therefore urgently needed. Huangbai liniment (HB) is a standardized herbal product clinically used to treat diabetic foot infections, including methicillin-resistant Staphylococcus aureusStaphylococcus aureus (MRSA). This trial assessed the efficacy and safety of HB for DFUs with mild MDRO infection.
    Methods: This multicenter, open-label, randomized controlled trial was conducted in China. A total of 154 patients with DFUs and mild MDRO infection were randomly assigned to the HB group and the silver dressing (SD) group. Both groups received the same basic treatment for diabetic foot disease. The HB group received Tazi therapy (topical application of HB) for 2 weeks, while the control group was treated with SD. Primary outcome was the resolution of infection defined as a change from mild infection to no infection (using the Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections). Secondary outcomes included the MDRO conversion rate, rate of completing ulcer healing, and reduction in ulcer size.
    Results: A total of 74 patients in the HB group and 63 patients in the SD group were included. Infection was resolved in 35 patients (47.3%) in the HB group versus 13 patients (20.6%) in the SD group (p = 0.001). Mixed-level logistic regression analyses showed that the HB group was associated with resolution of infection [odds ratio (OR) = 4.81; 95% confidence interval (CI): 2.01-12.48; p < 0.001]. However, there was no difference in rate of completing ulcer healing and reduction of ulcer size.
    Conclusion: Topical HB effectively facilitated mild infection resolution and MDRO conversion, with no adverse effects. HB is an effective and safe adjunctive therapy for short-term infection resolution in patients with DFU with mild MDRO infection. However, no evidence emerged for improved ulcer healing within 2 weeks. Longer follow-up is needed to assess wound healing outcomes.
    Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=66175., identifier ChiCTR2000041443.
    Keywords:  clinical trial; diabetic foot; infection; multidrug resistance; traditional Chinese medicine
    DOI:  https://doi.org/10.3389/fendo.2026.1926211
  23. J Clin Microbiol. 2026 Oct 27. e0087526
    Antibacterial Resistance Leadership Group
      The optimal phage susceptibility testing (PST) method is unclear. Here, two PST methods were compared using Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis enrolled in a placebo-controlled clinical trial of a single intravenous dose of a four-phage cocktail (WRAIR-PAM-CF1). In total, 508 P. aeruginosa sputum isolates were evaluated, including isolates collected before or after phage or placebo treatment, isolates from the same trial participants over time, and isolates of different colony morphologies from the same participants at the same time point. Susceptibility to phages PaWRA01Φ11, PaWRA01Φ39, PaWRA02Φ83, and PaWRA02Φ87 and a cocktail of all four phages was assessed using a plaque assay (PA) and a Biolog Omnilog-based liquid assay (LA) with the same bacterial inoculum. A total of 170/508 isolates (33%) and 195/508 isolates (38%) were identified as susceptible to the cocktail by PA and LA, respectively. Among the susceptible isolates, 169/170 (99%; PA) and 187/195 (96%; LA) also tested susceptible to at least one of the four phages in the cocktail. Susceptible percent agreement between the PA and LA ranged from 76% to 100% and non-susceptible percent agreement ranged from 89% to 100% for all phages studied and the cocktail. Phage PaWRA02Φ83 demonstrated the greatest individual activity, with 164/508 (32%) and 188/508 (37%) isolates testing susceptible by PA and LA, respectively. The four-phage cocktail provided numerically broader coverage of P. aeruginosa (i.e., had the highest susceptibility rate) than did any single phage. There was high concordance between PST results by PA and LA.IMPORTANCEStandardization of phage susceptibility testing (PST) methods is essential to support phage therapy trials and any future clinical implementation. There are no standardized PST methods or interpretive criteria for PST. In this study, PST was performed by a plaque assay and a Biolog Omnilog-based liquid assay on Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients enrolled in a clinical trial. Susceptibility of 508 isolates to four phages and a cocktail of all four was evaluated. There was high concordance between susceptibility assessed by plaque and liquid assays and numerically broader coverage of P. aeruginosa by the cocktail compared to any single phage. This manuscript should be of interest to those performing PST.
    Keywords:  Pseudomonas aeruginosa; cystic fibrosis; phage susceptibility testing
    DOI:  https://doi.org/10.1128/jcm.00875-26
  24. Int J Mol Sci. 2026 Oct 16. pii: 9170. [Epub ahead of print]27(20):
      Chronic rhinosinusitis (CRS) has traditionally been viewed as a chronic inflammatory disease in which microbial factors are implicated. However, increasing evidence suggests that CRS may be better understood as a disruption of sinonasal microbial homeostasis rather than as a chronic infection caused by a single pathogen. This review summarizes current knowledge on healthy sinonasal microbiome composition and function as well as microbial alterations in CRS. Particular attention is given to dysbiosis involving potentially pathogenic microorganisms, including Staphylococcus aureus and Pseudomonas aeruginosa, as well as biofilm formation and its interactions with the epithelial barrier and host immune response. We also discuss host-related, therapeutic, hormonal, and environmental factors that may contribute to microbial imbalance. Current evidence does not clearly establish whether dysbiosis is a cause or consequence of chronic inflammation. Based on the evidence synthesized here, we propose that CRS may be understood as a dynamic, bidirectional interaction between microbial imbalance and chronic inflammation, whereby microbial alterations may contribute to epithelial and immune dysregulation, while changes in the host environment influence the sinonasal ecosystem. By integrating these microbiological and host-related perspectives, this review provides a boarder framework for understanding CRS pathophysiology and guiding future research into individual patterns of sinonasal microbial homeostasis.
    Keywords:  Pseudomonas aeruginosa; Staphylococcus aureus; biofilm; chronic rhinosinusitis; dysbiosis; epithelial barrier; host–microbiome interactions; microbial homeostasis; sinonasal microbiome
    DOI:  https://doi.org/10.3390/ijms27209170
  25. Pathogens. 2026 Oct 08. pii: 1067. [Epub ahead of print]15(10):
      Antimicrobial resistance poses a major challenge to veterinary and human medicine, particularly in the context of difficult-to-treat infections caused by multidrug-resistant (MDR) bacteria. Pseudomonas aeruginosa, a WHO priority pathogen, is known for its resistance profile and ability to form biofilms. As an alternative to conventional antibiotics, bacteriophage therapy has gained attention due to its specificity for target bacteria, including those in biofilms, without disrupting the host microbiota. This study aimed to evaluate the antimicrobial potential of bacteriophages JG005 and JG024 against P. aeruginosa isolates obtained from companion animals, in their planktonic and biofilm forms. First, a total of 29 clinical isolates were characterized in terms of their antimicrobial resistance profile and biofilm-forming ability. Then, phage activity against planktonic cells was assessed using spot tests and time-kill assays, while antibiofilm activity was evaluated in a microplate assay. The results showed that 68.97% of the isolates were MDR and 41.38% were biofilm producers. JG005 and JG024 demonstrated activity against 58.62% and 65.52% of the isolates, respectively, with time-kill assays confirming strong growth inhibition. Antibiofilm activity was limited and observed after short phage exposure times. These findings support the potential of bacteriophages as a complementary strategy against resistant P. aeruginosa infections in animals.
    Keywords:  Pseudomonas aeruginosa; antimicrobial resistance; bacteriophage; biofilm; cats; dogs; planktonic cells
    DOI:  https://doi.org/10.3390/pathogens15101067
  26. J Cell Mol Med. 2026 Nov;pii: e71365. [Epub ahead of print]30(21):
      Systemic antibiotics are effective when used as adjunctive therapy in the treatment of periodontitis; however, their use must be balanced against antimicrobial resistance, which is a major threat to global public health. This review provides an expert synthesis of the literature and a field-level overview of antimicrobial resistance in periodontal therapy, highlighting current knowledge and emerging directions, while examining how adjunctive antibiotic protocols may contribute to resistance within the periodontal microbiome through emerging metagenomic insights. To provide this synthesis, the PubMed database was searched for English-language publications using combinations of the terms periodontitis, systemic antibiotics, antimicrobials, resistance, resistome, therapeutic adjuncts, resistance genes, susceptibility, antibacterial and drug resistance, and the findings are presented as a narrative review. The evidence indicates that a substantial proportion of patients with periodontitis harbour subgingival microbiota that are non-susceptible to at least one antibiotic used in periodontal therapy. Across the included studies, antimicrobial resistance was most frequently reported in Prevotella and Porphyromonas species, while some studies also identified virulence-associated factors in Staphylococcus aureus, a non-classical periodontal organism detected within the subgingival microbiota. Overall, current evidence indicates a high prevalence of antibiotic resistance genes in the subgingival microbiota of patients with periodontitis and highlights the ecological consequences of adjunctive antibiotic use. These findings reinforce the need to optimize antibiotic prescribing protocols within an antibiotic stewardship framework and support further metagenomic investigations to refine understanding of resistance patterns, gene-transfer mechanisms and microbiome disruption, with the aim of advancing precision-based periodontal care.
    Keywords:  antibacterial; antimicrobials; drug resistance; periodontitis; resistance; resistance genes; resistome; susceptibility; systemic antibiotics; therapeutic adjuncts
    DOI:  https://doi.org/10.1111/jcmm.71365
  27. Res Sq. 2026 Oct 05. pii: rs.3.rs-11232673. [Epub ahead of print]
      Early life gut microbiome dynamics are increasingly recognized as important determinants of microbiome maturation, yet the ecological dynamics of its associated bacteriophages remain poorly resolved. Here, we performed bulk and virus like particle (VLP)-enriched metagenomic sequencing and fecal metabolomic profiling of longitudinal fecal samples from 32 mother-infant dyads, incorporating an exogenous phage spike in to enable absolute quantification of viral loads. Our results show that early infant gut phageome is defined by a profound lack of virulent phage genome copies while temperate phages remain relatively stable, challenging previous assumptions. We further identified extensive maternal sharedness of mainly virulent phages predicted to infect Bacteroidaceae, which could explain recovery of virulent phage absolute abundances. Virulent phage concentrations were further associated with several fecal metabolites including primary bile acids. These findings revise the current model of infant phageome assembly highlighting the underappreciated role of virulent phages.
    DOI:  https://doi.org/10.21203/rs.3.rs-11232673/v1
  28. Wiad Lek. 2026 ;79(8): 1746-1751
       OBJECTIVE: Aim: To draw the medical community's attention to and outline the main causes of the rapid increase in antibiotic resistance among microorganisms in modern war.
    PATIENTS AND METHODS: Materials and Methods: Based on the microbiological examination of 2,288 samples from combat wounds, multidrug-resistant Gram-negative pathogens were found to predominate, particularly Klebsiella pneumoniae, Acinetobacter spp., and Pseudomonas aeruginosa, which were resistant to most antibiotics. The microbial load in all wounded patients exceeded 105 CFU/g.
    RESULTS: Results: The main factors contributing to the development of wound infection are the nature of injuries caused by modern weapons and the characteristics of the wound tract, tissue ischemia, impairment of local and systemic anti-infective defenses, and delayed medical care. In addition to clinical signs, the diagnosis of wound infection requires microbiological identification of the causative pathogens, assessment of laboratory markers, and imaging methods. The leading role of surgical debridement in the treatment of infected wounds and the importance of appropriate antibiotic therapy guided by antimicrobial susceptibility are emphasized. The effectiveness of negative-pressure wound therapy and local antibiotic administration is reviewed. The biological, medical, and social causes of antibiotic resistance are identified, and promising alternative treatment approaches, including bacteriophages and probiotics, are outlined.
    CONCLUSION: Conclusion: The management of wound infection requires a comprehensive approach combining surgical methods, appropriate antibiotic therapy, and innovative technologies, which is essential for improving treatment outcomes in wounded patients.
    Keywords:   antibiotic therapy ; bacteriophages ; multidrug-resistant microorganisms ; probiotics ; wounds ; wound infection
    DOI:  https://doi.org/10.36740/WLek/235899
  29. J Microbiol Methods. 2026 Oct 25. pii: S0167-7012(26)00374-X. [Epub ahead of print]251 107762
      Macroscale evaluation of bacteriophage host range frequently relies on visual interpretation of spot inoculation assays, in which clearing is recorded using qualitative or ordinal categories including +++, ++, +, and -. These categories are rapid and practical but compress continuous image variation and can introduce observer-dependent disagreement, particularly for weak and intermediate reactions. This study presents an open-source computer-vision platform that applies a defined image-reading procedure to arrayed phage spot assays by converting local clearing into a deterministic numerical measurement. The analytical signal is calculated from the relative grayscale-intensity difference between a predefined central spot region and spatially matched peripheral bacterial-lawn regions, providing local background normalization instead of reliance on absolute image brightness. Spatial positions are defined from plate anchors and proportional grid interpolation, allowing the same analytical logic to be applied to images with different dimensions after appropriate plate-specific calibration. The platform provides a continuous normalized spot-clearing score and an optional ordinal representation for compatibility with conventional reporting. Validation comprised 84 predefined spot reactions independently scored by four observers and four repeated computational analyses of identical image input. Manual scoring showed the greatest dispersion for weak and intermediate clearing, whereas automated re-analysis showed high repeatability. Automated scores also showed strong monotonic concordance with manual consensus. The platform is intended as a quantitative image-analysis layer for completed spot assays. The score does not measure plaque diameter or plaque number and does not independently establish productive phage infection, for which efficiency of plating (EOP) or other biological assays remain necessary.
    Keywords:  Antimicrobial susceptibility assessment; Computer vision-based image analysis; Digital standardization; Phage spot assay quantification; Phage-host interaction profiling; Reproducible computational microbiology
    DOI:  https://doi.org/10.1016/j.mimet.2026.107762
  30. Microorganisms. 2026 Oct 10. pii: 2308. [Epub ahead of print]14(10):
      Antimicrobial resistance (AMR) surveillance is increasingly strained by interconnected global crises, i.e., pandemics, climate change, armed conflicts, population mobility, and health inequalities, that disrupt healthcare delivery, diagnostic capacity, and laboratory infrastructure. In parallel, artificial intelligence (AI), machine learning, whole-genome sequencing, metagenomics, and digital surveillance offer the potential to shift from reactive reporting to predictive intelligence that anticipates resistance threats, although current implementations remain sector-specific, retrospective, and project-funded. Environmental surveillance, particularly wastewater monitoring coupled with genomic epidemiology, provides early warnings at population and ecosystem levels. The future integration of AI across human, animal, and environmental sectors could enable unified One Health intelligence; no such integrated platform is currently operational. This review focuses primarily on bacterial AMR. It examines how global drivers strain surveillance, how genomic, metagenomic, digital, and AI-enabled technologies reshape AMR detection and prediction, and the emerging non-antibiotic therapeutic landscape, including bacteriophage therapy, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based antimicrobials, antimicrobial peptides, microbiota-directed interventions, nanomedicine, host-directed therapies, photodynamic therapy, and vaccines. It then explores how these innovations can be integrated within a One Health framework to support coordinated global preparedness. Addressing the AMR crisis will require not only technological innovation but also equitable implementation, interdisciplinary collaboration, and resilient systems.
    Keywords:  One Health; antimicrobial resistance; artificial intelligence; digital surveillance; genomic surveillance; health inequalities; machine learning; metagenomics; wastewater surveillance; whole-genome sequencing
    DOI:  https://doi.org/10.3390/microorganisms14102308
  31. Am J Gastroenterol. 2026 Oct 28.
      Clostridioides difficile infection (CDI) is a major cause of morbidity, mortality, and healthcare utilization worldwide. Although advances in antimicrobial stewardship and infection prevention have reduced healthcare-associated disease in some settings, the incidence of community-associated CDI and the persistent burden of recurrent CDI (rCDI) continue to pose substantial clinical challenges. Because recurrent disease is fundamentally driven by persistent disruption of the intestinal microbiome and loss of colonization resistance, prevention has emerged as the central strategy for reducing long-term disease burden. This review summarizes contemporary evidence supporting prevention of both incident and rCDI, emphasizing practical approaches for gastroenterologists. Primary prevention centers on minimizing modifiable risk factors through antimicrobial stewardship, infection prevention and control, diagnostic stewardship to distinguish colonization from infection, and strategies to preserve the intestinal microbiome. For patients with CDI, we review evidence supporting extended antibiotic regimens, oral vancomycin prophylaxis during subsequent systemic antibiotic exposure, and microbiome restoration therapies, including conventional fecal microbiota transplantation and US Food and Drug Administration-approved microbiota-based therapies, which have transformed secondary prevention by restoring microbial diversity and colonization resistance. Special consideration is given to populations at particularly high risk for recurrence, including older adults, immunocompromised individuals, transplant recipients, and patients with inflammatory bowel disease. Finally, we discuss emerging preventive strategies, including precision risk stratification, microbiome- and metabolome-based biomarkers, bile acid modulation, and approaches targeting asymptomatic colonization. Together, these advances signal a paradigm shift from treating CDI episodes to implementing personalized preventive strategies that interrupt the cycle of recurrent disease and improve long-term patient outcomes.
    DOI:  https://doi.org/10.14309/ajg.0000000000004239
  32. Microorganisms. 2026 Oct 02. pii: 2214. [Epub ahead of print]14(10):
      Syndromic testing, defined as the simultaneous nucleic acid amplification-based detection of multiple potential pathogens and antimicrobial resistance (AMR) determinants directly from clinical specimens, has transformed laboratory diagnosis of infectious diseases in the United States over the past two decades. In contrast to traditional microbiology workflows that rely on culture, phenotypic susceptibility testing, and sequential single-target assays with turnaround times of 24-72 h or longer, syndromic multiplex panels provide comprehensive pathogen identification within 1-5 h, enabling timely clinical decision-making, targeted antimicrobial therapy, and improved patient outcomes. In this review, the current landscape of FDA-cleared syndromic testing panels across seven major clinical syndromes is examined, including respiratory tract infections, pneumonia, bloodstream infections, gastrointestinal infections, meningitis/encephalitis, joint and bone infections, and global febrile/travel-related illnesses. For each syndrome, commercially available panels in the United States are summarized, with emphasis on diagnostic performance, clinical applications, and limitations. Available evidence demonstrates that syndromic testing, when integrated with institutional diagnostic and antimicrobial stewardship programs, can reduce time to optimal therapy and unnecessary antimicrobial use and, in selected settings, shorten hospital length of stay. A mortality benefit has been reported in some patient populations, particularly those with bloodstream infections. Nevertheless, rapid turnaround time and earlier pathogen identification do not necessarily translate into timely clinical action and improved patient outcomes. Challenges related to implementation and optimization of appropriate panel utilization, including evolving AMR epidemiology, dynamic and geographically variable pathogen distributions, the critical role of diagnostic and antimicrobial stewardship, and emerging developments for diagnosis and management of infectious disease, are also discussed.
    Keywords:  NAAT; antimicrobial resistance; antimicrobial stewardship; bloodstream infection; diagnostic stewardship; gastrointestinal panel; joint infection; meningitis/encephalitis panel; multiplex PCR; pneumonia; respiratory panel; syndromic testing; tropical fever
    DOI:  https://doi.org/10.3390/microorganisms14102214
  33. Biomedicines. 2026 Oct 06. pii: 2255. [Epub ahead of print]14(10):
      Obesity is a heterogeneous multisystem condition characterized by chronic low-grade inflammation, oxidative stress, adipokine dysregulation, and insulin resistance; its effects on oral microbial homeostasis, tissue regeneration, and disease susceptibility vary with metabolic context and with the outcome examined. This narrative review synthesizes evidence on the mechanisms linking obesity to oral disease and on its implications for dental prevention, periodontal care, implant therapy, and oral surgery. MEDLINE via PubMed, Scopus, and Web of Science Core Collection were searched from January 2000 to 31 August 2026, with the final search performed on 10 September 2026. The strength of evidence differs markedly by outcome. Human epidemiological studies support an association with periodontitis; altered salivary flow and composition are reported mainly in cross-sectional studies. Proposed effects on osseous healing and jawbone remodeling rest substantially on experimental and systemic bone research, and specific marrow alterations remain poorly established. Obesity is associated with selected peri-implant inflammatory outcomes, whereas evidence on implant survival is less consistent; these findings establish neither impaired primary osseointegration nor a contraindication to implant therapy. Associations with caries appear largely attributable to shared determinants. The phenotype-aware framework proposed here is hypothesis-generating and requires prospective interventional validation.
    Keywords:  adipokines; insulin resistance; jawbone; metabolic syndrome; obesity; oral health; oral microbiome; peri-implantitis; periodontitis; wound healing
    DOI:  https://doi.org/10.3390/biomedicines14102255
  34. Vaccines (Basel). 2026 Oct 01. pii: 869. [Epub ahead of print]14(10):
      Typhoid fever, caused by Salmonella enterica serovars Typhi and Paratyphi, remains a major public health threat across Africa and Asia and causes substantial annual morbidity. Transmission persists in low- and middle-income countries (LMICs), where access to safe water and sanitation is limited. While improvements in water, sanitation, and hygiene (WASH) are essential, slow implementation makes vaccination the most practical preventive strategy. Current licensed vaccines have limitations, including suboptimal immune coverage in infants, limited duration of protection, and cold-chain requirements. This review examines bacteriophage-based vaccine platforms as emerging preclinical strategies for typhoid prevention. Phage technologies, including phage display, phage DNA, and hybrid models, offer potential advantages such as multivalent antigen display, projected thermostability, and cost-efficient production using bacterial manufacturing systems. Based on animal immunogenicity and proof-of-concept studies, these systems could theoretically induce durable immunity and broaden age-group protection, although their clinical feasibility and scalability remain unproven. We evaluate key technical hurdles, including endotoxin contamination, host-strain engineering, and payload-expression constraints. We also discuss how these potentially low-cost platforms may contribute to global antimicrobial resistance (AMR) mitigation efforts. Although phage-based vaccines remain in the preclinical stage, they represent promising research platforms for advancing vaccine equity and infectious disease resilience, provided regulatory and technical challenges are overcome. However, significant translational gaps must still be bridged before clinical application can be realized.
    Keywords:  DNA vaccines; Salmonella Typhi; antimicrobial resistance; bacteriophage vaccines; global health; phage display; typhoid conjugate vaccine; typhoid fever; vaccine development; vaccine platforms
    DOI:  https://doi.org/10.3390/vaccines14100869
  35. Nurs Open. 2026 Oct;pii: e70941. [Epub ahead of print]13(10):
       AIM: To describe the lived experiences and shared essential structure of recurrent diabetic foot ulceration among adults aged 65 years or older.
    DESIGN: A descriptive phenomenological study.
    METHODS: Seventeen participants were purposively recruited from a multidisciplinary diabetic foot clinic in China. Individual semi-structured interviews were conducted from October 2025 to February 2026 and analysed inductively using Colaizzi's seven-step method.
    RESULTS: Four themes were identified: (1) navigating recurrence: varied recognition, interpretations and responses; (2) pain and altered sensation: functional limitations and social participation; (3) living under the threat of amputation: distress, difficult decisions and acceptance and (4) relying on support while striving to preserve autonomy and dignity. The shared essential structure was continuing vulnerability after healing, alongside efforts to preserve control, autonomy and dignity.
    CONCLUSION: For older adults, recurrent diabetic foot ulceration was experienced as continuing vulnerability after healing, reshaping bodily confidence, everyday functioning, independence and future expectations.
    IMPLICATIONS FOR THE PROFESSION AND/OR PATIENT CARE: Care for older adults with recurrent diabetic foot ulceration should extend beyond wound management to assess recurrence recognition, sensory changes, pain, mobility and psychological distress, while supporting shared decision-making, rehabilitation, continuity of care and autonomy.
    IMPACT: This study identifies continuing vulnerability after healing, alongside efforts to preserve control, autonomy and dignity, as the shared experiential structure of recurrent diabetic foot ulceration in older adults, informing nursing and multidisciplinary care across settings.
    REPORTING METHOD: This study adhered to the Consolidated Criteria for Reporting Qualitative Research.
    PATIENT OR PUBLIC CONTRIBUTION: Patients were not involved as research partners in the design or conduct of the study. Seventeen older adults participated in interviews, and three subsequently reviewed a summary of the themes and shared essential structure.
    Keywords:  diabetic foot ulcer; lived experience; older adults; phenomenology; recurrence
    DOI:  https://doi.org/10.1002/nop2.70941
  36. Microorganisms. 2026 Oct 14. pii: 2355. [Epub ahead of print]14(10):
      Streptococcus pneumoniae (pneumococcus) represents a key clinical challenge, being a major global cause of morbidity and mortality. Typically existing as a nasopharyngeal commensal, pneumococcus undergoes significant metabolic changes during its switch to a virulent pathogen, when it can cause severe pneumoniae, bacteriemia and meningitis. This switch is poorly understood but is thought to be influenced by environmental signals arising from co-infections between pneumococcus and other bacteria as well as viruses in the nasopharynx. This review provides a comprehensive overview of the multi-stage progression of pneumococcal invasive disease, from initial colonisation to host barrier migration. We examine environmental triggers that drive the lifestyle switch from commensal to virulent, highlighting the role of other organisms in this stimulation. In particular, we focus on influenza A and respiratory syncytial virus, as well as other bacteria including Staphylococcus aureus, Moraxella catarrhalis and Haemophilus influenzae. Overall, we bring the current understanding of the field into the context of the growing antimicrobial resistance global threat, demonstrating that understanding these complex cross-species interactions is vital for developing clinical interventions against secondary pneumococcal infections.
    Keywords:  Streptococcus pneumoniae; co-infection; influenza; molecular mechanisms; respiratory syncytial virus
    DOI:  https://doi.org/10.3390/microorganisms14102355
  37. J Periodontol. 2026 Oct 27.
       BACKGROUND: Porphyromonas gingivalis peptidyl-arginine deiminase (PPAD) enzyme has been implicated in rheumatoid arthritis (RA) pathogenesis through protein citrullination and its potential contribution to neutrophil-associated inflammatory responses and anti-citrullinated protein antibody (ACPA) autoimmunity. However, its role in early stages of RA remains unclear. This study investigated the association of PPAD with citrullinated histone H3 (CitH3), cathelicidin (LL-37), and ACPA in preclinical RA (preRA), early RA (eRA), and established RA (RA), with and without periodontitis (PD).
    METHODS: 108 participants were categorized into preRA, eRA, RA, and nonRA controls with and without PD. Periodontal and rheumatological parameters were assessed. ppad gene expression was quantified in subgingival plaque samples, and salivary and serum levels of CitH3, LL-37 and ACPA were measured. Data were analyzed with SPSS version 26.
    RESULTS:  ppad expression was elevated in all PD groups, irrespective of RA status. Among PD groups, ppad correlated with salivary CitH3 only in eRA-PD (r = 0.628) and with serum ACPA only in RA-PD (r = 0.503), while no significant associations were detected between ppad and LL-37. CitH3 was not associated with serum ACPA in any PD group. As secondary findings, salivary CitH3 correlated with gingival bleeding index (GBI) in eRA-PD (r = 0.628) and RA-PD (r = 0.608) while serum LL-37 correlated with serum ACPA in eRA-PD (r = 0.767), CONCLUSION: Elevated ppad expression was primarily associated with PD rather than RA status. PPADs association with salivary CitH3 in eRA-PD suggests its strong role in periodontal inflammation during early phases of RA but disproves a mechanistic link between PPAD to NETs and RA.
    Keywords:  Porphyromonas gingivalis peptidyl‐arginine deiminase; anti‐citrullinated protein; neutrophil extracellular trap; periodontitis; rheumatoid arthritis
    DOI:  https://doi.org/10.1002/jper.70213
  38. Int J Mol Sci. 2026 Oct 16. pii: 9212. [Epub ahead of print]27(20):
      Acinetobacter baumannii (A. baumannii) is an important cause of healthcare-associated infections due to its remarkable capacity for environmental persistence and multidrug resistance. The quorum-sensing (QS) network, particularly the AbaI/AbaR system, contributes to the regulation of several traits involved in colonization and infection. Current evidence indicates that AbaI/AbaR-mediated signalling coordinates biofilm formation, surface-associated motility, antimicrobial tolerance via modulation of efflux pump activity, oxidative stress responses and membrane integrity, as well as biofilm-associated antibiotic resistance and stress adaptation. QS also influences interactions with host cells, including epithelial damage and modulation of innate immune responses, although its role in adaptive immunity remains largely unresolved. This review summarises current knowledge of the molecular mechanisms underlying AbaI/AbaR-mediated signalling, its role in regulating A. baumannii infection-relevant phenotypes and host-pathogen interactions. It also discusses the therapeutic potential of quorum-quenching (QQ) strategies for attenuating A. baumannii virulence, as well as their current limitations in infection control.
    Keywords:  Acinetobacter baumannii; biofilm; quorum quenching; quorum sensing; virulence
    DOI:  https://doi.org/10.3390/ijms27209212
  39. J Intern Med. 2026 Oct 25.
      Periodontitis is a common chronic inflammatory disease that has traditionally been considered primarily within the domain of dentistry. Increasing evidence, however, associates periodontitis with systemic inflammatory conditions, particularly atherosclerotic cardiovascular disease. Dysbiotic subgingival microbial communities, disruption of the periodontal epithelial barrier, transient bacteremia, microbial products, and locally generated inflammatory mediators provide biologically plausible pathways through which periodontal inflammation may influence systemic vascular biology. Epidemiologic and mechanistic studies support an association between periodontitis and cardiovascular disease, although direct causality has not been established. Importantly, periodontal treatment has been associated with improvement in endothelial function and reductions in selected systemic inflammatory biomarkers, but evidence that treatment prevents myocardial infarction, stroke, or cardiovascular mortality remains insufficient. For the practicing internist, the principal message is therefore both practical and appropriately cautious: Periodontal health should be recognized as one component of overall health, and closer collaboration between physicians and dental professionals may strengthen preventive care. This Perspective reviews the clinical evidence linking periodontitis with systemic disease, using cardiovascular disease as the principal example, and considers its implications for prevention, interdisciplinary care, and future research.
    Keywords:  atherosclerosis; cardiovascular disease; endothelial dysfunction; oral health; periodontitis; prevention; systemic inflammation
    DOI:  https://doi.org/10.1111/joim.70176
  40. Microorganisms. 2026 Oct 06. pii: 2274. [Epub ahead of print]14(10):
      Aeromonas salmonicida is an important threat to the sustainability of aquaculture production and a major contributor to antimicrobial resistance, which has encouraged bacteriophage therapy. This review evaluated the current evidence base for bacteriophage therapy against A. salmonicida. Literature searches were carried out in Scopus, PubMed, and Web of Science prior to 2 April 2026, according to PRISMA 2020 guidelines. After removing 46 duplicate records, a final dataset of 108 unique publications was obtained for analysis. A data extraction form was created to include studies examining bacteriophage activity against A. salmonicida. Information about phage properties' experimental conditions' treatment outcomes, and study methods was extracted. Study quality and translation potential were evaluated with a qualitative appraisal tool, and a narrative synthesis was chosen due to significant heterogeneity. A total of 22 studies met the inclusion criteria; however, most were conducted in vitro, with few in vivo. Because of heterogeneity in phage-host systems, study designs, and outcomes, systems cannot be compared. Overall' bacteriophage therapy is a promising targeted treatment to address A. salmonicida infection. Evidence from these studies suggests more controlled studies' phage genome safety assessment' evaluation of phage resistance development' and field trials are necessary before the adoption of these treatments.
    Keywords:  antimicrobial resistance (AMR); aquaculture disease management; bacterial resistance mechanisms; furunculosis; lytic infection cycle; phage-host interaction
    DOI:  https://doi.org/10.3390/microorganisms14102274
  41. Front Nutr. 2026 ;13 1863436
       Background: Although tibial transverse transport (TTT) may promote wound repair in complex diabetic foot ulcer (DFU), reliable indicators reflecting postoperative recovery remain limited. This study aimed to investigate the association of nutritional-immune indicators and their dynamic changes with DFU severity and wound healing time after TTT treatment.
    Methods: This retrospective cohort study included 227 DFU patients who underwent TTT between January 2023 and May 2024. Patients were classified according to Wagner grades. LASSO regression and multivariable logistic regression were used to identify nutritional-immune factors associated with DFU severity, with ROC curve analysis, calibration analysis, and decision curve analysis performed to evaluate model performance. In addition, 147 patients with complete 1-month postoperative laboratory data were analyzed using Cox proportional hazards regression, Kaplan-Meier analysis and time-dependent ROC analysis to evaluate the association between dynamic nutritional-immune changes and subsequent wound healing time.
    Results: Compared with non-severe DFU patients, severe DFU patients showed greater inflammatory activation and nutritional-immune disturbances. Multivariable logistic regression identified ANLR (OR = 0.993, 95% CI: 0.987-0.999, p = 0.020) and PNI (OR = 0.909, 95% CI: 0.853-0.969, p = 0.004) as independently associated with DFU severity. The model incorporating ANLR and PNI showed good discrimination for severe DFU (AUC = 0.825, 95% CI: 0.756-0.893). Baseline PNI and ANLR were not associated with postoperative wound healing time, whereas greater ΔPNI was independently associated with a higher hazard of subsequent wound healing in the severity-stratified Cox model (HR = 1.030, 95% CI: 1.008-1.053, p = 0.008). Kaplan-Meier analysis showed faster wound healing in patients with greater ΔPNI (log-rank p = 0.018).
    Conclusion: PNI and ANLR are associated with DFU severity and may provide complementary information for preoperative risk stratification. An increase in PNI at 1 month after TTT is associated with subsequent wound healing time and may represent an integrated response of nutritional-immune status during the treatment course.
    Keywords:  diabetic foot ulcer; nutrition; prognosis; prognostic nutritional index; tibial transverse transport
    DOI:  https://doi.org/10.3389/fnut.2026.1863436
  42. Antibiotics (Basel). 2026 Oct 06. pii: 983. [Epub ahead of print]15(10):
       BACKGROUND: Antimicrobial resistance (AMR) is a major global health threat, while conventional diagnostic, stewardship, dosing, and drug-development strategies remain limited by diagnostic delays, population-level decision-making, and a shrinking antibiotic pipeline. Artificial intelligence (AI) may help address these gaps by integrating complex clinical, microbiological, genomic, pharmacological, and chemical data.
    METHODS: We conducted a narrative review of English-language publications issued between 1 January 2010 and 27 August 2026. PubMed/MEDLINE, Scopus, and Web of Science were searched using a prespecified combination of terms related to AI, machine learning, AMR, diagnosis, susceptibility prediction, antimicrobial stewardship, precision dosing, pharmacokinetics, pharmacodynamics, and antibiotic discovery. A separate structured search of ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform, and ISRCTN was performed on 27 August 2026 to identify prospective interventional studies.
    RESULTS: AI-based systems demonstrated promising performance in differentiating bacterial from viral infections, predicting bacteremia and sepsis, enhancing matrix-assisted laser desorption/ionization time-of-flight interpretation, estimating antimicrobial susceptibility, supporting individualized empirical therapy, optimizing antibiotic dosing, and accelerating compound discovery. However, external and temporal validation frequently produced substantially poorer performance than internal validation. In representative resistance-prediction studies, AUROC declined from 0.94 internally to 0.55 during temporally independent external validation and by 0.10-0.25 over 18 months. Moreover, the structured registry search identified five prospective interventional studies of AI-based applications and one additional randomized study of conventional model-informed precision dosing.
    CONCLUSIONS: Current evidence demonstrates that AI can generate technically promising predictions, but it does not yet establish consistent clinical or economic benefit. Discrimination alone is insufficient to demonstrate clinical usefulness. Prospective multicenter trials, clinically meaningful outcome measures, external validation, continuous monitoring for model drift, and formal implementation and cost-effectiveness evaluations are required before widespread adoption.
    Keywords:  antibiotic discovery; antimicrobial resistance; antimicrobial stewardship; artificial intelligence; machine learning; precision dosing
    DOI:  https://doi.org/10.3390/antibiotics15100983
  43. Antibiotics (Basel). 2026 Oct 01. pii: 970. [Epub ahead of print]15(10):
      Human milk is increasingly recognized as a complex biological system that contributes to infant development through nutritional, immunological, and microbial pathways. Simultaneously, antimicrobial stewardship (AMS) has become a global healthcare priority because of rising antimicrobial resistance and concerns regarding the ecological consequences of antibiotic exposure during early life. This narrative review examines current evidence regarding the impact of anti-infective therapies during lactation on the maternal-infant microbiome axis and discusses the role of AMS in supporting appropriate maternal treatment while preserving breastfeeding. While previous reviews have independently described the biological properties of human milk or general antimicrobial resistance, this narrative review uniquely bridges these domains by framing the infant microbiome as a clinical endpoint for pharmacological governance. The primary objective is to synthesize current evidence on the relationships among human milk, the infant gut microbiome, and neurodevelopment, with a novel emphasis on how integrating Antimicrobial Stewardship (AMS) and microbiome-conscious prescribing during lactation actively safeguards these developmental trajectories. This work contributes to the existing literature by shifting the focus from observational biology to an actionable clinical framework for healthcare providers. A structured literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science. Studies addressing human milk biology, infant gut microbiota development, antimicrobial exposure during lactation, microbiota-gut-brain interactions, and stewardship strategies were reviewed. Available evidence indicates that breastfeeding promotes the establishment of a beneficial gut microbiota and supports immune maturation through the combined action of human milk oligosaccharides, immunological factors, and milk-associated microorganisms. Maternal and neonatal antibiotic exposure may alter microbial colonization patterns; however, the magnitude, persistence, and long-term clinical significance of these effects remain incompletely understood. Although mechanistic studies support biologically plausible links between microbiome alterations and neurodevelopmental pathways, direct evidence connecting maternal antibiotic use during lactation with adverse neurodevelopmental outcomes is limited. Current evidence supports continued breastfeeding during most maternal antibiotic treatments and highlights the importance of microbiome-conscious prescribing. AMS strategies based on diagnostic appropriateness, treatment optimization, and avoidance of unnecessary antibiotic exposure may help minimize microbial disruption while ensuring effective infection management.
    Keywords:  anti-infective therapy; antimicrobial stewardship; breastfeeding; human milk; infant gut microbiota; lactation; microbiome; neurodevelopment
    DOI:  https://doi.org/10.3390/antibiotics15100970
  44. ACS Biomater Sci Eng. 2026 Oct 27.
      Biofilm-associated infections caused by Staphylococci remain a major challenge in the context of biomedical implants due to their tolerance to antibiotics and resistance to host defenses. Here, we report the identification of a novel phage-derived depolymerase (DPO2) targeting staphylococcal biofilms and its integration into hyaluronic acid-based layer-by-layer (LbL) coatings. DPO2 was produced recombinantly and proved more effective preventing biofilm formation than destroying preformed Staphylococcus epidermidis biofilms. DPO2 antibiofilm activity was retained and even enhanced upon immobilization within DPO2/Hyaluronic Acid multilayered coatings. The resulting functionalized surfaces exhibited potent inhibition of biofilm formation by multiple S. epidermidis and Staphylococcus aureus strains from orthopedic infections, reaching nearly complete suppression under the tested conditions. This work demonstrates the potential of combining phage-derived enzymes with biomaterial surface engineering to develop efficient, non-antibiotic antibiofilm strategies. Such coatings represent a promising approach for preventing implant-associated infections.
    Keywords:   Staphylococcus aureus ; Staphylococcus epidermidis ; bacteriophage depolymerase; biofilm; layer-by-layer coating
    DOI:  https://doi.org/10.1021/acsbiomaterials.6c01098
  45. Sci Adv. 2026 Oct 30. 12(44): eaeh7105
      The escalating crisis of antimicrobial resistance, particularly among Gram-negative bacteria, demands innovative therapeutic strategies. Here, we present a dual-targeting lipid nanoparticle-chimeric phage (AbLCP) system engineered to combat multidrug-resistant (MDR) Gram-negative bacteria. Our design integrates a genetically modified M13 phage displaying anti-lipopolysaccharide (LPS) antibodies with polymyxin B conjugation, which is further encapsulated within anti-LPS antibody-functionalized lipid nanoparticles. This system overcomes the fundamental limitations of conventional phage therapy, enabling efficient cellular internalization, endosomal escape, and potent intracellular bactericidal activity. In murine models of Pseudomonas aeruginosa infection, AbLCP achieved superior bacterial clearance and up to 103-fold reduction in bacterial burden at a 103-fold lower effective dose than free polymyxin B, with 67-fold selective accumulation at infection sites, and attenuated systemic inflammation and preservation of gut microbiota. Mechanistically, AbLCP neutralized LPS to suppress inflammation and induced a lethal bacterial stress response. This work establishes a transformative nanophage platform that merges synthetic biology with nanomedicine, offering a promising strategy against MDR bacterial infections.
    DOI:  https://doi.org/10.1126/sciadv.aeh7105
  46. Clin Infect Dis. 2026 Oct 28. 83(4): 499-513
      Native joint septic arthritis (NJSA) is a time-sensitive orthopedic and infectious diseases emergency associated with substantial morbidity, mortality, and long-term functional impairment. This State-of-the-Art Review synthesizes current evidence on NJSA epidemiology with a primary focus on bacterial etiologies, risk factors, pathogenesis, microbiology, clinical presentation, and diagnostic challenges, including the absence of validated diagnostic criteria and limitations of culture-based evaluation. We summarize current diagnostic approaches with a focus on synovial fluid interpretation and the expanding role of molecular diagnostics. Management principles emphasize timely surgical source control, appropriate antimicrobial therapy, and coordinated multidisciplinary care. Outcomes are reviewed through the lens of relapse, reinfection, and functional recovery, highlighting the influence of host factors, joint involvement, and timeliness of intervention. Finally, we identify persistent gaps in evidence including optimal surgical timing, treatment duration, oral transition, clinical utility of emerging diagnostics, and outline research priorities to improve NJSA care and outcomes.
    Keywords:  antimicrobial therapy; diagnostic evaluation; epidemiology; microbiology; molecular diagnostics; native joint septic arthritis; outcomes; pathogenesis; source control; synovial fluid analysis
    DOI:  https://doi.org/10.1093/cid/ciag473
  47. Antibiotics (Basel). 2026 Oct 16. pii: 1030. [Epub ahead of print]15(10):
      Background: It is estimated that approximately 20-30% of women suffer from recurrent urinary tract infections (rUTIs). The disease is primarily bacterial, especially Escherichia coli, making antibiotics the standard treatment. Increasing antibiotic resistance of uropathogens reduces treatment effectiveness. Therefore, non-antibiotic approaches are increasingly being investigated for the management of rUTIs. This narrative review provides a comprehensive overview of currently available and emerging methods of treatment and prevention of rUTIs in women. Methods: This paper employs a narrative review with a structured literature search and synthesizes data from three major databases, including PubMed, Web of Science, and Scopus. The review was conducted in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) checklist. Scientific articles were searched using the following keywords: 'recurrent urinary tract infections in women', 'antibiotic prophylaxis', 'immunoprophylaxis', 'urinary microbiome'. Results: Observational evidence has reported an association between continuous antibiotic prophylaxis and severe outcomes, including pyelonephritis and septicemia; however, these findings are susceptible to confounding by indication and should not be interpreted as evidence of a causal relationship. Clinical studies suggest that immunomodulatory approaches, such as OM-89 bacterial lysate, next-generation polybacterial mucosal vaccines (e.g., MV140), and oral immunostimulants, have potential to reduce the frequency of rUTI recurrences in women, although the strength and certainty of evidence vary between interventions. Bacteriophage therapy is an emerging and exploratory targeted approach supported by early clinical and experimental evidence, but its efficacy for preventing recurrent uncomplicated UTIs remains uncertain, though rapid development of phage resistance remains a potential limitation. Prophylactic strategies, including Lactobacillus-based probiotics, low-dose estriol, and microbiota transplantation, have shown preliminary or variable results, with limited evidence for rUTI prevention. In particular, findings on vaginal dysbiosis and microbiota modulation should not be interpreted as a direct evidence of rUTI prevention. Conclusions: While antibiotic therapy remains essential, continuous prophylaxis may contribute to antimicrobial resistance and disrupt microbial balance. Therefore, novel therapeutic strategies are still being studied. Several non-antibiotic strategies, including immunoprophylaxis and microbiome modulation, represent potential preventive approaches, whereas bacteriophage therapy and vaginal microbiota transplantation remain exploratory and require further clinical validation. Their preventive efficacy against rUTIs remains unestablished. Moreover, antimicrobial peptides (AMPs), nanotechnology, molecularly targeted therapies, and precision medicine strategies are being investigated. Plant-based therapies may provide benefit, but their clinical efficacy remains to be established. Overall, further clinical studies are needed to confirm the preventive efficacy of these emerging approaches.
    Keywords:  antibiotic prophylaxis; immunoprophylaxis; recurrent urinary tract infections in women
    DOI:  https://doi.org/10.3390/antibiotics15101030
  48. Microorganisms. 2026 Oct 08. pii: 2290. [Epub ahead of print]14(10):
      Bacterial biofilms possess inherent physical barriers and structural heterogeneity. These features pose a major obstacle to clinical anti-infective therapy. This review systematically examines the dynamic interplay between phages and bacterial biofilms, which ranges from antagonistic competition to synergistic interaction. It aims to dissect the underlying mechanisms and translational potential of phages as next-generation precision anti-infective agents. A core scientific question in phage-biofilm interactions is how phages penetrate and remodel the three-dimensional extracellular matrix of biofilms. Classic mechanisms include direct lysis of bacteria embedded in biofilms, degradation of matrix scaffolds by phage-derived exopolysaccharide depolymerases, and modulation of bacterial virulence and biofilm phenotypes via lysogenic conversion. Auxiliary mechanisms encompass synergistic bactericidal effects of phages and the host's innate immune system, as well as niche competition within microbial communities. Recently identified mechanisms involve phage-mediated interference with bacterial quorum sensing, physical remodeling of biofilm spatial architecture, and enhanced antibiotic penetration across biofilm barriers. These processes collectively shape the microenvironmental network linking phages, bacteria, and host cells. By synthesizing the complex phage-biofilm interplay, this review provides a theoretical basis for designing engineered phage cocktails, optimizing phage-antibiotic combination regimens, and developing intelligent biomaterial delivery systems. These delivery systems are intended for targeted treatment of chronic biofilm-associated infections.
    Keywords:  antagonism; biofilm; phage; phage therapy; phage–biofilm interaction; synergism
    DOI:  https://doi.org/10.3390/microorganisms14102290
  49. Environ Microbiol Rep. 2026 Dec;pii: e70454. [Epub ahead of print]18(6):
      Microbial ecosystems can now be measured across genomic, transcriptomic, proteomic, metabolomic, and environmental dimensions, yet their emergent functions remain difficult to predict and control. Artificial intelligence (AI) can integrate heterogeneous data, but predictive accuracy alone does not establish causality, transferability, or controllability. This review developed a five-layer framework: observe, infer, predict, design, and learn that connects microbial measurement to prospective intervention and experimental feedback. We critically synthesise evidence from sequence and protein learning, multi-omics integration, metabolic modelling, synthetic microbial communities, environmental biotechnology, and temporal forecasting. Recent primary studies illustrate progress in forecasting community trajectories, predicting microbial competition and designing consortia for pollutant degradation; they also reveal important boundaries between model performance and demonstrated ecosystem control. We examine risks arising from compositional data, information leakage, dependent observations, batch effects, uncertain calibration, sparse perturbation data, ecological instability, and evolutionary change. We propose operational criteria for ecosystem programmability and a staged validation pathway from controlled systems to field-relevant environments. Progress will depend on standardised context-rich data, hybrid AI-mechanistic models, prospective benchmarks, independent replication, and safety-constrained design.
    Keywords:  artificial intelligence; mechanistic modelling; microbial ecology; microbiome engineering; synthetic microbial communities
    DOI:  https://doi.org/10.1111/1758-2229.70454
  50. Int Wound J. 2026 Nov;pii: e71080. [Epub ahead of print]23(11):
      Although difficult social interaction patterns are scientifically addressed in other medical fields, it is an under-researched topic in wound care. A knowledge gap exists pertaining to what kind of interpersonal problems occur between patients with chronic wounds, their relatives and nurses. In an exploratory interview study, we analyzed 37 interviews with nurses from different settings to explore how they perceive and approach difficult encounters with patients with chronic wounds. A content analysis conducted with MAXQDA revealed three broad themes of difficult nurse-patient interactions. First, conflicts included aggression, violence, insults, arguments, unrealistic demands, discrimination, lying, complaints, and general unfriendly behaviour. Often, nurses function as a kind of outlet for patients' annoyance. Second, non-adherence was associated with perceiving treatment as difficult. Third, difficult but non-conflictual situations were also common, that is, various and multilayered issues which complicate treatment. In addition, an overview of what respondents considered an ideal wound care practitioner is provided. Interventions could target self-care, nonviolent communication, and health literacy.
    Keywords:  chronic wounds; emotional burden; interpersonal conflicts; non‐adherence; nurse–patient interaction
    DOI:  https://doi.org/10.1111/iwj.71080
  51. Viruses. 2026 Oct 19. pii: 1159. [Epub ahead of print]18(10):
      Microbiologically influenced corrosion (MIC) caused by sulfate-reducing bacteria (SRB) is a major challenge in industrial infrastructure, yet the limited availability of well-characterized bacteriophages has hindered the development of phage-based strategies for controlling these organisms. Here, we present an integrated genome-guided workflow for the discovery, validation, and synthetic reconstruction of endogenous prophages from the model sulfate-reducing bacterium Desulfovibrio vulgaris Hildenborough. Bioinformatic analysis using PHASTEST identified seven prophage-like regions distributed throughout the bacterial chromosome, including five classified as intact prophages. Ultraviolet (UV)-mediated induction followed by whole-genome sequencing of purified phage DNA experimentally validated four inducible prophage loci (Regions 1, 5, 6 and 7) detected in all three biological replicates, together with a fifth locus (Region 2) detected less consistently, demonstrating strong agreement between computational prediction and biological activity. Comparative analysis further showed that prophage functionality was not always correlated with computational completeness, as one computationally "questionable" region exhibited robust induction whereas another "intact" region remained inactive under the conditions tested. Based on these results, one highly inducible prophage was selected for synthetic engineering. Three progressively truncated synthetic prophage genomes (approximately 36, 33, and 29 kb) were assembled using long-range PCR and scarless isothermal DNA assembly and verified by Nanopore sequencing, which confirmed accurate reconstruction without detectable rearrangements. Following electroporation into D. vulgaris and UV induction, the engineered genomes produced reproducible localized turbid phenotypes rather than classical lytic plaques, indicating that the synthetic constructs remained biologically active but did not undergo efficient lytic propagation under the experimental conditions examined. Quantitative PCR analysis of representative structural and lytic genes in wild-type cells revealed coordinated transcriptional activation by 21 h after UV induction, defining a practical harvest time for subsequent characterization. Collectively, this work establishes an integrated computational and synthetic biology framework for engineering endogenous prophages from anaerobic SRB. The approach provides a foundation for investigating temperate phage biology in D. vulgaris and represents an important step toward the future development of engineered phage platforms for MIC control.
    Keywords:  Desulfovibrio vulgaris; PHASTEST; bacteriophage; microbiologically influenced corrosion; phage genome engineering; prophage induction; sulfate-reducing bacteria; synthetic genome assembly
    DOI:  https://doi.org/10.3390/v18101159
  52. J Clin Med. 2026 Oct 16. pii: 8024. [Epub ahead of print]15(20):
      Objectives: To evaluate the impact of heart failure (HF) on one-year outcomes in patients hospitalized for diabetic foot ulcers (DFUs). Methods: A retrospective observational study including consecutive patients admitted in 2024 to a tertiary multidisciplinary diabetic foot service for DFUs. Patients were stratified according to the presence of HF (HF+ vs. HF-). One-year outcomes included wound healing, major amputation, non-fatal major adverse limb events (NF-MALCE), including myocardial infarction, stroke, recurrent chronic limb-threatening ischaemia (CLTI) requiring revascularization, and mortality. Results: Overall, 270 patients were included (104 HF+ [38.5%] vs. 166 HF- [61.5%]). Patients with HF exhibited a more severe cardiorenal phenotype, with worse cardiac and renal biomarkers. At one-year follow-up, patients with HF showed lower wound healing rates than patients without HF (58.6% vs. 71.7%, p = 0.03), higher incidence of NF-MALCE (43.3% vs. 18.7%, p < 0.001), mainly driven by recurrent CLTI requiring revascularization (48.9% vs. 27.0%, p < 0.001), and higher mortality (21.1% vs. 7.2%, p = 0.001). Conversely, no differences were observed in major amputation, myocardial infarction, or stroke. After multivariable adjustment for age, sex, ischaemic heart disease, atrial fibrillation, dialysis, haemoglobin, albumin, foot infection and peripheral arterial disease (PAD), HF remained independently associated with NF-MALCE (adjusted odds ratio (aOR) 2.90, 95% confidence interval (CI) 1.38-6.09, p = 0.005) and recurrent CLTI requiring revascularization (aOR 2.43, 95% CI 1.11-5.32, p = 0.026); the association remained consistent in the subgroup with PAD. Conclusions: HF identifies a high-risk cardio-renal phenotype and is independently associated with increased limb-related adverse events in patients hospitalized for DFUs, supporting closer vascular surveillance and integrated multidisciplinary cardio-renal-foot care.
    Keywords:  diabetic foot ulcer; heart failure; limb-related outcomes; peripheral arterial disease; recurrent limb ischaemia
    DOI:  https://doi.org/10.3390/jcm15208024
  53. Wiad Lek. 2026 ;79(8): 1776-1782
       OBJECTIVE: Aim: To identify periodontopathogenic bacteria in periodontal pockets and subgingival plaque of patients with periodontitis in Karbala, Iraq, using 16S rRNA gene sequencing, the gold standard for molecular identification of microorganisms.
    PATIENTS AND METHODS: Materials and Methods: Molecular techniques based on 16S rRNA gene analysis provide reliable identification of bacterial species associated with periodontal infections. A crosssectional study was conducted with 26 patients, ranging in age from 20 to 50 years. The patients were excluded of the study if they had been on systemic antibiotics or periodontal therapy within the past three months. Every sample was aseptically collected with informed consent. The sterile paper points were used to take sample of the subgingival plaque, and they were inserted in the deepest periodontal pockets with a duration of 20 30 seconds. The samples were instantly frozen in sterile microtubes with transport buffer and frozen at -20 o C until further molecular analysis.
    RESULTS: Results: The study population consisted of 65.38% females and 34.62% males. The most frequent clinical findings were gingival bleeding (55%) and inflammation (33%), with no significant differences observed between sexes. Molecular analysis revealed a high prevalence of Porphyromonas gingivalis (20/26) and Tannerella forsythia (18/26). Veillonella parvula was detected in 12 patients, while Treponema denticola was identified in 11 patients. Actinobacillus actinomycetemcomitans and Fusobacterium nucleatum were detected at lower frequencies, in 3 and 2 patients, respectively. Successful amplification of the 16S rRNA gene was confirmed by the presence of a ~1500 bp band in all samples.
    CONCLUSION: Conclusions: Sequencing PCR is a powerful tool for the diagnosis of the subgingival microbiota in periodontitis, showing that Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola are the most frequently encountered pathogens in the sampled population. Moreover, the strong link between Treponema denticola and diabetes mellitus highlights the need to take into account systemic health factors when analysing microbiological data.
    Keywords:   16S rRNA ; periodontal diseases ; Porphyromonas gingivalis
    DOI:  https://doi.org/10.36740/WLek/222501
  54. Clin Oral Investig. 2026 Oct 27. pii: 548. [Epub ahead of print]30(11):
       BACKGROUND: Periodontitis is increasingly recognized as a chronic inflammatory disease with systemic implications beyond the oral cavity. Within perio-medicine, its association with cardiovascular disease has been extensively investigated, particularly in relation to atherosclerotic cardiovascular disease (ASCVD). However, the field is now expanding toward a broader and more phenotype-specific cardiovascular framework.
    OBJECTIVE: This narrative review critically examines how the periodontitis-cardiovascular field has evolved from a predominantly ASCVD-centered model toward a broader spectrum of cardiovascular phenotypes, with particular emphasis on differences in evidence maturity, contemporary mechanistic concepts, and unresolved translational questions.
    METHODS: A structured literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library. Evidence from mechanistic, observational, and interventional studies was qualitatively synthesized according to its contribution to established clinical associations, supportive mechanistic evidence, emerging cardiovascular phenotypes, and unresolved questions regarding causality and clinical translation.
    RESULTS: The association between periodontitis and coronary atherosclerotic disease represents the most mature component of the literature, with substantial observational and meta-analytic support, while ischemic cerebrovascular disease is also supported by consistent but more heterogeneous evidence. Beyond ASCVD, atrial fibrillation and heart failure currently represent the most developed emerging cardiovascular phenotypes, whereas evidence concerning abdominal aortic aneurysm and venous thromboembolism remains more preliminary and hypothesis-generating. Contemporary mechanistic models extend beyond bacteremia and systemic inflammation to include endothelial dysfunction, thrombo-inflammatory signaling, trained immunity, immune-cell trafficking, functional dysregulation of the oral microbiome, and shared biological vulnerabilities. However, these pathways differ markedly in cardiovascular-specific evidentiary maturity and should not be interpreted as equivalent evidence of human causality. Periodontal therapy can improve inflammatory biomarkers, endothelial function, selected metabolic parameters, and blood pressure in specific populations, but a persistent translational gap remains between surrogate-marker improvement and demonstrated reduction in major adverse cardiovascular events. Periodontitis may also contribute to chronic systemic inflammatory burden in susceptible individuals, although its role within cardiovascular residual inflammatory risk remains an emerging hypothesis.
    CONCLUSIONS: The periodontal-cardiovascular field is evolving from a predominantly ASCVD-centered model toward a phenotype-specific continuum of evidence maturity. Periodontitis is best interpreted as a potential modifier of cardiovascular vulnerability rather than as an established causal determinant. Future research should prioritize adequately powered cardiovascular-outcome trials, standardized periodontal phenotyping, and prospective validation of emerging phenotypes and mechanistic frameworks before periodontal information can be considered clinically actionable for cardiovascular prevention.
    Keywords:  Atherosclerosis; Cardiovascular disease; Cerebrovascular disease; Endothelial dysfunction; Inflammation; Periodontitis
    DOI:  https://doi.org/10.1007/s00784-026-07234-7
  55. Front Endocrinol (Lausanne). 2026 ;17 1966400
       Background: Human β-defensin-3 (hBD-3) is an epithelial-derived antimicrobial peptide involved in innate immunity and tissue repair, but its clinical association with diabetic foot infection (DFI) remains insufficiently characterized.
    Objective: To evaluate the associations of serum hBD-3 with prevalent DFI and infection severity and to assess its discriminatory performance alone and in combination with conventional inflammatory markers.
    Methods: This retrospective study included 150 participants: 30 healthy controls, 30 patients with diabetes without foot disease, and 90 patients with diabetic foot disease, including 30 without infection and 60 with DFI. Logistic regression and LASSO penalized regression were used to identify factors associated with prevalent DFI and moderate/severe infection. Restricted cubic spline analyses explored nonlinear associations. Discriminatory performance was evaluated using receiver operating characteristic curves, and internal validation was performed with 1,000 bootstrap resamples.
    Results: Serum hBD-3 was higher in patients with DFI than in those with non-infected diabetic foot disease [108.9 (86.3, 141.5) vs. 69.8 (56.1, 84.7) pg/mL, P < 0.001] and increased with infection severity. Higher hBD-3, CRP, PCT, and HbA1c and lower albumin were independently associated with prevalent DFI. The final prevalent-DFI model included HbA1c, albumin, hBD-3, CRP, and PCT and achieved an apparent AUC of 0.928, with an optimism-corrected AUC of 0.895. The moderate/severe DFI model included hBD-3, CRP, and PCT and achieved an apparent AUC of 0.935 and an optimism-corrected AUC of 0.917. RCS analyses suggested nonlinear associations between hBD-3 and both prevalent DFI and infection severity.
    Conclusion: Serum hBD-3 was associated with the presence and severity of DFI and provided complementary discriminatory information beyond conventional inflammatory markers. The combined models showed promising performance but remain exploratory and require prospective multicenter external validation before clinical application.
    Keywords:  diabetic foot infection; diagnostic discrimination; human β-defensin-3; infection severity; inflammatory markers
    DOI:  https://doi.org/10.3389/fendo.2026.1966400
  56. Mol Biol Rep. 2026 Oct 25. pii: 1811. [Epub ahead of print]53(1):
      Culture-based information on oral Bacillus recovered from adults with periodontitis remains limited, particularly for endospore-forming isolates related to the Bacillus cereus sensu lato complex. We characterized 11 Bacillus isolates (PCP01-PCP11) recovered from purposively selected oral swab specimens from adults with periodontitis. The isolates were evaluated for morphology, motility, catalase and oxidase activities, hemolysis, thermotolerance, nitrate reduction, lecithinase activity, and 16 S rRNA gene sequence similarities. All isolates were gram-positive, endospore-forming rods; 10/11 were motile, 11/11 were catalase-positive, 8/11 exhibited β-hemolysis, 8/11 grew at 50 °C, 9/11 reduced nitrate, and 6/11 were lecithinase-positive. All isolates grew under both aerobic and anaerobic conditions, supporting a facultatively anaerobic growth phenotype. Primers 27 F/1492R generated approximately 1.5-kb amplicons, from which an approximately 909-bp common high-quality region was retained after bidirectional sequencing and trimming. BLASTn and neighbor-joining analyses supported affiliation with Bacillus, with several isolates showing the closest sequence affinity to the reference taxa within the B. cereus sensu lato. Because partial 16 S rRNA sequences provide insufficient resolution within the B. cereus sensu lato complex, reference matches were interpreted only as genus- or group-level affinities for the species. Sex-stratified phylogenetic patterns were considered descriptive because female- and male-derived isolates were analyzed against different reference sets, precluding population-level inferences from the analysis. Overall, this study provides preliminary phenotypic and phylogenetic characterization of cultured oral Bacillus and highlights the need for systematic sampling and genome-resolved taxonomic classification of oral Bacillus species.
    Keywords:   Bacillus ; 16S rRNA; Periodontitis; culture-based isolation; oral microbiota; phenotypic characterization
    DOI:  https://doi.org/10.1007/s11033-026-12998-y
  57. Diagn Microbiol Infect Dis. 2026 Oct 23. pii: S0732-8893(26)00458-X. [Epub ahead of print]117(1): 117707
      Bacterial infections remain a major global health challenge, which are responsible for significant morbidity, mortality, and increasing antimicrobial resistance worldwide. Rapid and accurate identification of bacterial pathogens is therefore essential for guiding appropriate antimicrobial therapy, improving patient outcomes, and supporting effective infection control strategies. However, conventional microbiological diagnostic methods such as culture, microscopy, and biochemical testing are often time-consuming, labor-intensive, and dependent on expert interpretation. In recent years, artificial intelligence (AI) has increasingly emerged as a powerful tool capable of transforming clinical microbiology by enabling rapid analysis of complex biomedical data. This review aims to provide a comprehensive overview of the role of AI in the diagnosis and identification of bacterial pathogens and to discuss its current applications, advantages, limitations, and future perspectives. Key AI-assisted technologies, including machine learning and deep learning algorithms such as Random Forest, Support Vector Machines, Artificial Neural Networks, and Convolutional Neural Networks, are increasingly applied to diagnostic platforms, including automated microscopy, next-generation genomic sequencing, MALDI-TOF mass spectrometry, and clinical data analysis systems. Current evidence indicates that AI-assisted diagnostic approaches can substantially improve the speed, accuracy, and automation of microbial pathogen detection while enabling large-scale analysis of microbiological and clinical datasets. In the future, AI-integrated microbiology laboratories, rapid diagnostic platforms, genomic surveillance systems, and AI-assisted clinical decision support tools are expected to further enhance infectious disease diagnostics and contribute to improved antimicrobial stewardship and global infection management.
    Keywords:  Antimicrobial resistance detection; Artificial intelligence; Bacterial pathogen identification; MALDI-TOF mass spectrometry; Machine learning; Next-generation sequencing
    DOI:  https://doi.org/10.1016/j.diagmicrobio.2026.117707
  58. iScience. 2026 Nov 20. 29(11): 117985
      Periodontitis has been proposed as a potential contributor to lung cancer (LC), but the epidemiological, mechanistic, and clinical evidence remains heterogeneous. This structured narrative review evaluates the association between periodontitis and LC, the directness of proposed biological mechanisms, and the implications for risk assessment and supportive care. Observational studies generally report positive associations, although effect estimates vary according to periodontal ascertainment, study population, and adjustment for smoking. Clinically assessed periodontitis, self-reported or administrative diagnoses, tooth loss, periodontal-associated microbial markers, and general oral microbiome profiles represent distinct exposure domains and should not be interpreted interchangeably. The absence of a clear association among lifelong never smokers and the lack of supportive Mendelian randomization evidence further limit causal inference. Human studies demonstrate oral-lower airway microbial overlap, while experimental LC models support microbiota-related inflammatory and oncogenic signaling; however, periodontal origin, directional microbial transmission, and a continuous causal pathway from periodontitis to LC have not been established. Clinically, periodontitis should not modify current eligibility for low-dose computed tomography (LDCT) screening, and oral or respiratory microbiome biomarkers remain investigational. Perioperative oral care has comparatively stronger evidence for reducing postoperative pulmonary infectious complications, but this benefit should not be extrapolated to tumor recurrence or survival. Overall, current evidence supports an observational association and biological plausibility, whereas independent causality and an oncologic benefit of periodontal treatment remain unproven.
    Keywords:  lung cancer; lung microbiome; oral microbiome; oral-lung axis; periodontitis; perioperative oral care
    DOI:  https://doi.org/10.1016/j.isci.2026.117985
  59. J Med Internet Res. 2026 Oct 29. 28 e103362
       BACKGROUND: AI-enabled patient profiling has been proposed to organize heterogeneous patient data and support personalized nursing care and health support. Given the growing use of AI, machine learning, large language models (LLMs), digital phenotyping, and digital twins in health care, it is important to clarify how patient profiling has been conceptualized, applied, and evaluated in nursing-relevant contexts.
    OBJECTIVE: This scoping review aimed to examine and report the available evidence on AI-enabled patient profiling for personalized nursing care and health support.
    METHODS: This scoping review was conducted using the Joanna Briggs Institute methodological framework and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Chinese and English databases were searched from inception to May 18, 2026, including China National Knowledge Infrastructure, Wanfang Data, VIP Database, Chinese Biomedical Literature Database, PubMed, CINAHL, Web of Science, and Embase. Eligible studies used AI or computational intelligence methods to construct, classify, apply, validate, or evaluate patient profiles or related patient representations relevant to personalized nursing care or health support. Two reviewers independently screened records, assessed full texts, and charted data using a predefined form. Data were synthesized descriptively and narratively using an input-process-output framework.
    RESULTS: A total of 61 studies were included. AI-enabled patient profiling was represented through patient profiles, patient or user personas, digital phenotypes, patient segments, clinical subtypes, digital twins, and LLM-enabled personalization. Included studies used diverse data sources, including electronic health records, nursing records, patient-reported outcomes, questionnaires, mobile app data, wearable and sensor data, engagement logs, and textual or conversational data. Common AI approaches included machine learning, clustering, deep learning, natural language processing, recommender systems, knowledge graphs, digital twin modeling, and LLMs. Applications focused on personalized education, self-management support, rehabilitation, chronic disease management, remote monitoring, decision support, follow-up care, and shared decision-making. Most studies evaluated algorithmic performance, feasibility, usability, or system development, whereas fewer studies examined profile validity, actionability, equity, workflow integration, or long-term nursing-sensitive and patient-centered outcomes.
    CONCLUSIONS: Existing evidence positions AI-enabled patient profiling as an emerging data-to-action mechanism for personalized nursing care and health support rather than as a mature clinical intervention. Future research should strengthen conceptual clarity, validate the profile, establish explicit pathways linking profiles to actions, incorporate nurse and patient involvement, assess equity and safety, and evaluate implementation in real-world nursing settings.
    TRIAL REGISTRATION: OSF Registry mey4u; https://osf.io/mey4u.
    Keywords:  AI; artificial intelligence; clinical decision support; digital health; machine learning; nursing care; patient profiling; patient-centered care; personalized care
    DOI:  https://doi.org/10.2196/103362
  60. Life (Basel). 2026 Oct 07. pii: 1670. [Epub ahead of print]16(10):
      Drug-resistant biofilm infections remain a major challenge for medical devices and implants. Biofilm formation can reduce antimicrobial effectiveness through physiological heterogeneity, tolerance, persistence, and interactions with the host and biomaterial surface. Antimicrobial biomaterials have been developed to prevent colonization, detect infection, provide antimicrobial activity, control established biofilms, and support tissue recovery. However, their performance depends on the biological context in which they function. This review examines these strategies through interactions among the host, microbe, and material, using carbapenem-resistant Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus, and carbapenem-resistant Pseudomonas aeruginosa as selected biological stress-test examples for evaluating biomaterial performance. It also considers the limitations in current evaluation, including planktonic testing, biological conditioning, microbial adaptation, effects on non-target microorganisms, material stability, manufacturing, and clinical translation. Antimicrobial activity alone does not establish effective performance in infection. Material function must match the microbial state, host environment, and intended clinical use while maintaining host compatibility and function during use. We propose infection resilience as a design framework organized around Prevent, Detect, Respond, Resolve, and Regenerate. Infection resilience refers to coordinated material performance under changing microbial and host conditions rather than the number of functions incorporated into a material. This framework offers a practical basis for more biologically relevant evaluation and purposeful design of antimicrobial biomaterials for drug-resistant biofilm infections.
    Keywords:  antibiotic resistance; antimicrobial biomaterials; antimicrobial surfaces; biofilm control; biomaterial-associated infection; drug-resistant biofilms; host-microbe-material interactions; infection-resilient interfaces; medical devices
    DOI:  https://doi.org/10.3390/life16101670
  61. Commun Med (Lond). 2026 Oct 25. pii: 556. [Epub ahead of print]6(1):
      In the era of CFTR modulators, cystic fibrosis (CF) is being profoundly reshaped for treatment-eligible individuals. Theratyping, an ex vivo strategy assessing individual responses to CFTR modulators, supports precision medicine, particularly for rare variants where conventional trials are limited. In this Review, we discussed advances in CF disease modelling, highlighting strengths, limitations and translational relevance. We also outlined future directions aligned with the Replacement, Reduction, and Refinement (3 R) ethical principles in animal research, including organ-on-a-chip technologies, to improve mechanistic insight and preclinical predictivity. CF research offers therefore a paradigmatic framework for therapeutic innovation in other rare genetic diseases.
    DOI:  https://doi.org/10.1038/s43856-026-01965-0
  62. Antibiotics (Basel). 2026 Sep 30. pii: 964. [Epub ahead of print]15(10):
      Crohn's disease (CD) is a chronic inflammatory disorder characterized by complex interactions among genetic susceptibility, environmental factors, dysregulated immune responses, and alterations of the intestinal microbiota. Although corticosteroids, immunomodulators, biologics, and advanced small-molecule therapies remain central to disease management, a substantial proportion of patients experience primary non-response, loss of response, or treatment-related adverse effects. This has stimulated interest in complementary therapeutic strategies targeting host-microbe interactions and intestinal microbial homeostasis. This review critically examines emerging microbiome-directed approaches for CD, with particular emphasis on pathobionts such as adherent-invasive Escherichia coli (AIEC). We discuss the available evidence for antibiotics, antimicrobial peptides (AMP), gut bacteriophages, fecal microbiota transplantation (FMT), and selected nutraceutical and dietary interventions. While some approaches show promising biological or clinical signals, the strength of evidence varies considerably, ranging from in vitro and animal studies to randomized clinical trials and meta-analyses. Antibiotic therapies targeting intestinal pathogens have shown heterogeneous results, suggesting the need for pathogen-guided and intracellularly active antimicrobial strategies. Novel approaches, including AIEC-specific phages and AMP-based interventions, represent promising microbiome-sparing alternatives capable of selectively modulating disease-associated microorganisms. Furthermore, FMT and nutraceuticals may contribute to restoring microbial balance and strengthening intestinal homeostasis, although their efficacy requires further validation in controlled clinical trials. Overall, these strategies support a transition toward precision medicine approaches integrating microbial profiling, host immune characterization, and targeted antimicrobial interventions to improve therapeutic outcomes in CD.
    Keywords:  Crohn’s disease; active Crohn’s disease; adherent-invasive Escherichia coli; antibiotics; antimicrobial peptides; fecal microbiota transplantation; gut bacteriophages; microbiota; nutraceuticals; precision medicine
    DOI:  https://doi.org/10.3390/antibiotics15100964
  63. Diagnostics (Basel). 2026 Oct 09. pii: 3282. [Epub ahead of print]16(20):
      Periodontal and peri-implant diseases cause progressive tissue destruction that may lead to tooth and implant loss. Conventional clinical and radiographic assessments document accumulated tissue damage but provide limited information on current biological activity or healing. This narrative review synthesizes the literature published between 2015 and 2025, identified through searches of PubMed/MEDLINE, Scopus, and Web of Science, on salivary biomarkers in periodontal and peri-implant diseases, with emphasis on diagnostic performance, changes after therapy, and clinical translation. Salivary inflammatory mediators and tissue- and bone-remodeling markers-including interleukin (IL)-1β, IL-6, IL-8, IL-17, tumor necrosis factor-α, matrix metalloproteinase (MMP)-8, MMP-9, calprotectin, and the RANKL/osteoprotegerin axis-are consistently associated with periodontal and peri-implant disease. Multimarker panels generally outperform single biomarkers, with some studies reporting areas under the curve above 0.90 for periodontitis detection; however, most evidence derives from cross-sectional diagnostic studies, and prospective prognostic data remain limited. We propose the "salivary healing signature" as a conceptual framework-not a validated test-in which serial multimarker measurements could complement clinical assessment for disease detection, risk stratification, and treatment monitoring. Standardized sampling and analytical protocols, control of confounders, defined thresholds, and prospective validation in diverse populations are required before clinical implementation.
    Keywords:  healing signature; inflammatory cytokines; matrix metalloproteinases; peri-implantitis; periodontitis; point-of-care diagnostics; salivary biomarkers; treatment monitoring
    DOI:  https://doi.org/10.3390/diagnostics16203282
  64. Expert Rev Anti Infect Ther. 2026 Oct 29.
       INTRODUCTION: Antimicrobial resistance (AMR) represents a critical global health threat, surpassing the pace of discovery and clinical development of new antimicrobial agents. Therefore, innovative therapeutic strategies are urgently needed to enhance antibiotic efficacy, overcome multidrug-resistant infections, and limit resistance development. Smart liposomal nanoplatforms have emerged as promising tools capable of improving antimicrobial therapy through targeted delivery, enhanced bacterial uptake, biofilm penetration, protection against enzymatic degradation, and controlled drug release.
    AREAS COVERED: This review examines recent advances in the rational design of evolved liposomes, including stimuli-responsive and programmable systems, for combating resistant bacterial infections. It discusses their ability to improve pharmacokinetic and pharmacodynamic profiles, overcome biological barriers, and enable precision antimicrobial delivery. Current translational challenges, including large-scale manufacturing, physicochemical characterization, regulatory requirements, and clinically relevant preclinical models, are critically evaluated. Emerging strategies, such as artificial intelligence-driven formulation optimization, continuous microfluidic manufacturing, multifunctional therapeutic platforms incorporating gene editing, and next-generation antibiotic-adjuvant combination strategies, are also explored.
    EXPERT OPINION: Liposomal drug-delivery systems may improve the exposure, distribution, and intracellular or local delivery of antimicrobial agents, but improved delivery should not be equated with reversal of bacterial resistance. Successful clinical translation will depend on formulation- and infection-specific evidence, clinically relevant preclinical models, controlled and scalable manufacturing, and appropriate regulatory frameworks, while artificial intelligence, digital-twin, and precision-medicine approaches are best viewed as decision-support tools that complement experimental and clinical validation.
    Keywords:  antimicrobial resistance; artificial intelligence; biofilm eradication; clinical translation; nanomedicine; precision anti-infective therapy; smart liposomes
    DOI:  https://doi.org/10.1080/14787210.2026.2756297
  65. Antibiotics (Basel). 2026 Sep 24. pii: 950. [Epub ahead of print]15(10):
       BACKGROUND/OBJECTIVES: Antimicrobial resistance has renewed interest in bacteriophage cocktails as antibacterial and adjunctive agents, but the global research landscape and the bacterial determinants that constrain cocktail performance have not been mapped within a single framework. We quantified global phage-cocktail research and tested whether antibiotic-resistance, phage-receptor, and biofilm gene sets converge on shared genes in three Gram-negative pathogens representing three bacterial orders.
    METHODS: The Web of Science Core Collection was searched on 5 July 2026 (query "phage" and "cocktail"). After deduplication and screening, 1598 articles and reviews (1992-2026) were analyzed with bibliometric workflows, citation-burst and co-citation analyses, and a focused China-United States comparison. Because these are the two leading producers and represent the dominant biocontrol and clinical research models, the comparison is deliberately restricted to them and is not presented as a global ranking. Resistance (R), phage receptor/defense (P), and biofilm (B) gene sets were curated for Pseudomonas aeruginosa PAO1, Escherichia coli K-12, and Acinetobacter baumannii ATCC 17978; overlaps were tested by one-sided hypergeometric tests with Benjamini-Hochberg correction and against size-matched control gene sets, followed by STRING protein-protein interaction and KEGG/GO enrichment. Orthologous conservation was assessed with KEGG Orthology in addition to gene-symbol matching.
    RESULTS: Annual output grew from 2 records (1992-1996) to 873 (2022-2026; 54.6% of the corpus), led by the USA (322 records) and China (292). Phage-receptor-biofilm overlaps were strongly enriched in all three species (29, 7, and 28 genes; odds ratios 47.0, 8.1, and 31.7; all P ≤ 7.6 × 10-5), whereas resistance-phage-receptor overlaps were strongly enriched in PAO1 (18 genes; odds ratio 17.7) and K-12 (26 genes; odds ratio 30.2) but not in A. baumannii (9 genes; odds ratio 1.8; P = 0.088). Four unrelated control gene sets showed no enrichment in any species (odds ratios 0-1.9; P ≥ 0.42). Candidate networks formed alginate, Psl-Pel, lipopolysaccharide-modification, and SOS/porin modules; KEGG enrichment converged on biofilm formation and cationic antimicrobial peptide resistance; 14 of the 18 symbol-level conserved genes were corroborated by shared KEGG Orthology assignments.
    CONCLUSIONS: Phage-cocktail research has entered a phase of rapid growth, with hotspots converging on combination therapy and formulation. Biofilm-matrix synthesis and surface-appendage assembly form a transferable interface between phage adsorption and biofilm formation across three bacterial orders, whereas the coupling between antibiotic resistance and phage-receptor genes is lineage-restricted. Because the R, P, and B sets overlap by construction, these convergences are hypothesis-generating and require experimental validation before they can be used as design rules.
    Keywords:  Acinetobacter baumannii; antimicrobial resistance; bacteriophage; bibliometric analysis; biofilm; gene network; phage cocktail
    DOI:  https://doi.org/10.3390/antibiotics15100950
  66. Int J Chron Obstruct Pulmon Dis. 2026 ;21 649518
      Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disorder characterized by persistent airflow limitation, progressive functional decline, and recurrent exacerbations. Increasing evidence indicates that microbiome alterations in COPD extend beyond the airways and involve coordinated changes across respiratory and intestinal compartments. Importantly, these alterations are dynamic rather than static, varying across stable disease, disease progression, acute exacerbations, and distinct inflammatory phenotypes. Changes in the gut microbiome are accompanied by alterations in microbial metabolites, particularly short-chain fatty acids and tryptophan-derived metabolites, as well as impaired intestinal barrier integrity and systemic inflammatory responses. Emerging evidence from respiratory samples further suggests that airway microbial functional features and local metabolic alterations may contribute to pulmonary host responses, although respiratory microbial metabolites remain less extensively characterized. Experimental studies further suggest that microbiome-derived signals can modulate neutrophils, macrophages, T-cell balance, and innate lymphoid cells, thereby influencing pulmonary inflammation and tissue injury. Fecal microbiota transplantation studies provide additional evidence that disease-associated microbial communities can modify susceptibility to smoke-induced lung injury, supporting a potential causal contribution of the gut microbiome. Meanwhile, probiotics, dietary fiber, short-chain fatty acid supplementation, macrolides, and traditional Chinese medicine or natural products have shown preliminary microbiome-associated benefits, although clinical evidence remains limited and heterogeneous. This review summarizes dynamic airway and gut microbiome alterations across the course of COPD, integrates current evidence on microbial metabolism, intestinal barrier dysfunction, and immune responses, and evaluates emerging microbiome-related therapeutic strategies. Future studies should prioritize longitudinal multi-compartment sampling, standardized microbiome methodology, mechanistic validation, and adequately powered clinical trials to determine whether microbiome modulation can provide reproducible clinical benefit in defined COPD populations.
    Keywords:  chronic obstructive pulmonary disease; gut–lung axis; microbial metabolites; microbiota dysbiosis; microbiota-targeted interventions
    DOI:  https://doi.org/10.2147/COPD.S649518
  67. J Biol Eng. 2026 Aug 01. pii: 157. [Epub ahead of print]20(1):
      The human microbiome provides a robust ecosystem for mucosal barrier function, immune regulation, metabolism, and resistance to pathogen infection. Dysbiosis causes inflammatory bowel disease, oral inflammation, wound damage, skin disease, and cancer-related immune dysregulation. Current probiotic therapy is limited by low survival during storage and administration, low oral bioavailability, short retention time, and insufficient targeting. Probiotic-hydrogel systems combine viable microorganisms with natural or synthetic polymer networks to promote probiotic protection, local retention, and controlled release. They can also incorporate prebiotics, engineered bacteria, oxygen-releasing agents, antioxidants, growth factors, drugs, or advanced manufacturing techniques such as microfluidics and 3D printing. Recent preclinical studies suggest that probiotic-hydrogel can modulate local microbes, suppress pathogens, control inflammation, support barrier repair, and promote tissue regeneration. However, most evidence is far from clinical, and human data are limited to a small number of oral and periodontal applications. In this review, we summarize the design strategies, encapsulation approaches, mechanistic frameworks, disease-based evidence, and translational challenges of probiotic-hydrogel. In particular, we paid attention to evidence level, safety, manufacturing, regulatory classification, product stability, clinical trial design. Such issues need to be well understood before probiotic-hydrogel can move from experimental platforms to clinically applicable microbiome treatments.
    Keywords:  Combination therapy; Hydrogels; Microbiome; Probiotics; Translational medicine
    DOI:  https://doi.org/10.1186/s13036-026-00740-y
  68. Microbiol Mol Biol Rev. 2026 Oct 28. e0014526
      SUMMARYThe ESKAPE group of pathogens represents one of the most critical threats to global health due to their capacity to evade antimicrobial treatments. This review provides a structured synthesis of the literature addressing antimicrobial resistance mechanisms, epidemiological relevance, clinical impact, and emerging strategies for containment within a One Health framework. Relevant studies and surveillance reports were analyzed to characterize the global distribution and burden of these organisms across human, animal, and environmental settings. The evidence indicates that ESKAPE pathogens remain leading causes of healthcare-associated infections while increasingly being identified in non-clinical reservoirs, highlighting the interconnected nature of antimicrobial resistance. Recent findings point to sustained high morbidity and mortality associated with these pathogens, driven by the expansion of multidrug-resistant lineages, and the limited effectiveness of current therapeutic options. Key challenges identified include gaps in surveillance integration, the spread of resistance determinants across sectors, and variability in infection control practices. Addressing these issues requires coordinated strategies that integrate surveillance, antimicrobial stewardship, infection prevention, and the development of novel therapeutics within a comprehensive One Health approach.
    Keywords:  ESKAPE; One Health; epidemiology; resistance mechanisms
    DOI:  https://doi.org/10.1128/mmbr.00145-26
  69. Front Microbiol. 2026 ;17 1947768
       Introduction: Phage-derived depolymerases, primarily located in phage tail fiber and tail spike proteins, have emerged as promising antibacterial and antivirulence agents capable of degrading bacterial surface polysaccharides and thereby combating multidrug-resistant bacterial infections. Despite the growing volume of publications in this interdisciplinary domain, a systematic bibliometric synthesis of the global research landscape remains absent.
    Methods: Publications indexed from 2010 to 2025 were retrieved from the Web of Science Core Collection (WOSCC) and Scopus on April 26, 2026. After deduplication and relevance screening, 326 records were retained. Bibliometric analyses and visualizations were performed using R with the bibliometrix package, VOSviewer and CiteSpace.
    Results: Annual publication output increased from 3 records in 2010 to 51 in 2025 and fitted an exponential growth model, indicating sustained expansion of the field. China and the United States were the most productive countries/regions, whereas Belgium and Poland showed the highest citation impact among leading contributors. The University of Wrocław and the Russian Academy of Sciences emerged as prominent institutional hubs. Keyword co-occurrence analysis identified three major thematic directions: phage discovery and genomic characterization, antibacterial and antibiofilm applications, and mechanistic or structural studies of depolymerase activity, with Klebsiella pneumoniae being the most frequently studied bacterial target.
    Conclusion: This bibliometric analysis systematically maps the 16-year landscape of phage depolymerase-enabled anti-infective research, delineating the leading forces and thematic evolution that have shaped the field. These trends highlight promising avenues for mechanistic studies on the structural basis of depolymerase substrate specificity and preclinical research on formulation, safety, and manufacturing, supporting the translational development of depolymerase-related anti-infectives.
    Keywords:  Klebsiella pneumoniae; anti-infective; bacteriophage; bibliometric analysis; biofilm; phage-derived depolymerase
    DOI:  https://doi.org/10.3389/fmicb.2026.1947768
  70. Pathogens. 2026 Oct 02. pii: 1044. [Epub ahead of print]15(10):
      Respiratory pathogens remain a major global public health concern due to factors including their genetic diversity, dynamic transmission patterns, and increasing antimicrobial resistance. Conventional molecular diagnostics, particularly polymerase chain reaction (PCR)-based assays, remain essential for rapid and scalable pathogen detection but provide limited information on pathogen evolution, transmission, and resistance mechanisms. Advances in whole-genome sequencing (WGS), targeted sequencing, and metagenomic next-generation sequencing (mNGS) have expanded respiratory pathogen surveillance from targeted detection toward higher-resolution genomic characterization. However, no single technology can adequately address all surveillance objectives. Instead, molecular diagnostics, genomic sequencing, epidemiological investigation, and clinical assessment provide complementary information that can be integrated according to the pathogen, clinical context, and specific public health question. This review examines the evolution of respiratory pathogen surveillance and emphasizes an integrated framework in which different technologies are selected and combined to support pathogen characterization, transmission investigation, antimicrobial resistance surveillance, and preventive decision-making. We further discuss emerging applications of artificial intelligence (AI) for integrating genomic, epidemiological, and clinical data, with potential roles in genomic interpretation, early risk assessment, and precision infection control. Although AI-enhanced surveillance remains largely at the research and validation stage, advances in data integration, model development, and computational infrastructure may enable more predictive and actionable surveillance systems. Overall, the future of respiratory pathogen surveillance will depend not simply on adopting more advanced technologies, but on integrating complementary detection and analytical approaches to transform pathogen detection into actionable evidence for public health decision-making.
    Keywords:  artificial intelligence; genomic surveillance; metagenomic sequencing; molecular diagnostics; public health surveillance; respiratory pathogens; whole-genome sequencing
    DOI:  https://doi.org/10.3390/pathogens15101044
  71. Antibiotics (Basel). 2026 Sep 27. pii: 957. [Epub ahead of print]15(10):
       BACKGROUND: Most acute gastrointestinal infections are self-limiting, but antibiotics remain essential for selected patients with severe, invasive, or high-risk disease. This narrative review examines when antibiotics should be started or withheld in adults and children with suspected or confirmed bacterial gastrointestinal infection, which regimens should be selected, and how treatment should be reassessed after diagnostic and susceptibility results become available.
    METHODS: PubMed and Scopus were searched for relevant English-language evidence published from 1 January 2014 through 28 August 2026. Google Scholar was used for supplementary citation tracking, and landmark earlier studies and major international guidelines were also considered. The search informed a narrative synthesis and was not conducted as a systematic review. Sixty-one sources were included.
    RESULTS: The evidence base is uneven. Recommendations concerning rehydration, avoidance of antibiotics in Shiga toxin-producing Escherichia coli infection, and treatment of Clostridioides difficile infection (CDI) are comparatively consistent. By contrast, treatment thresholds and durations for several enteric infections rely largely on observational evidence, indirect evidence, or expert consensus. Antibiotics should generally be withheld in uncomplicated watery diarrhea and used selectively for dysentery, severe travelers' diarrhea, cholera, enteric fever, invasive salmonellosis, and CDI. Regimen selection should reflect host risk, illness severity, travel exposure, and local susceptibility data. Therapy should be narrowed or discontinued after diagnostic clarification whenever appropriate.
    CONCLUSIONS: The principal stewardship priorities are appropriate patient selection, culture and susceptibility testing when the results may change management, and use of the shortest effective regimen supported by the available evidence.
    Keywords:  antibiotic therapy; antimicrobial resistance; antimicrobial stewardship; gastroenteritis; infectious diarrhea; precision medicine
    DOI:  https://doi.org/10.3390/antibiotics15100957
  72. GMS Infect Dis. 2026 ;14 Doc08
       Background: Urinary tract infections are among the most prevalent bacterial infections worldwide, with Escherichia coli as the leading pathogen. Conventional diagnostic methods, including urine culture and antimicrobial susceptibility testing, require 48-72 hours, often delaying targeted therapy and promoting empirical antibiotic use, thereby exacerbating antimicrobial resistance.
    Objective: This review summarizes advances in point-of-care diagnostic technologies for rapid detection and antimicrobial susceptibility testing in localized or uncomplicated urinary tract infections.
    Methods: A comprehensive literature review of studies published between 2008 and 2025 was conducted using MeSH and free-text searches for "point-of-care testing", "urinary tract infection", "rapid diagnostics", and related terms. Included studies described the mechanisms, performance, and clinical applicability of emerging point-of-care systems.
    Results: Thirty-four studies met inclusion criteria. Paper-based assays, lateral-flow tests, microfluidic devices, and hydrogel biosensors demonstrated rapid bacterial detection (from <5 min to 6 h) with variable sensitivities (10-106 CFU/mL). Among commercial devices, the Sysmex PA-100 antimicrobial susceptibility testing (AST) system provided phenotypic antimicrobial susceptibility testing within 30-45 minutes and achieved over 95% specificity compared with standard microbiology, while the Lodestar DX (LAMP-based) and Bosch Vivalytic (PCR-based) systems enabled molecular identification of uropathogens and resistance genes within 40-146 minutes.
    Conclusions: Point-of-care diagnostic platforms substantially reduce diagnostic turnaround, improve antibiotic stewardship, and offer cost-effective alternatives to conventional culture. The Sysmex PA-100 system currently represents the most clinically validated phenotypic point-of-care tool for uncomplicated urinary infections management. Future research should focus on expanding diagnostic panels, validating clinical outcomes, and facilitating integration into primary care and antimicrobial stewardship programs.
    Keywords:  antimicrobial resistance; antimicrobial susceptibility testing; phenotypic detection; point-of-care testing; urinary tract infections
    DOI:  https://doi.org/10.3205/id000108
  73. Viruses. 2026 Oct 12. pii: 1131. [Epub ahead of print]18(10):
      The gastrointestinal tract contains a dense multi-kingdom ecosystem in which bacteria, fungi, archaea, viruses, the mucosa, and the immune system interact. Although cancer microbiome research has focused mainly on bacteria, the gut virome dominated by bacteriophages may influence gastrointestinal carcinogenesis by reshaping bacterial communities, transferring functional genes, modulating inflammation, and altering treatment response. The strongest evidence comes from colorectal cancer, where multiple cohorts show altered phage diversity, temperate-phage enrichment, disrupted phage-bacteria networks, and reproducible stool-based diagnostic signals. Emerging studies in pancreatic cancer, esophageal adenocarcinoma, hepatocellular carcinoma, and precursor lesions suggest that virome disruption extends beyond colorectal cancer, although evidence remains uneven. Classic oncogenic viruses, including Epstein-Barr virus and hepatitis viruses, provide complementary examples of direct viral carcinogenesis in digestive organs. Anelloviruses are widespread in healthy individuals and are not established causes of cancer, but their abundance and composition may reflect immune status, inflammation, tissue injury, and altered host viral ecology. Virome-related interventions remain clinically immature: fecal microbiota transplantation has reached small phase I/II studies in gastrointestinal cancers, whereas phage, fecal-filtrate, and fecal virome approaches remain preclinical or non-oncology; direct oncolytic viruses have reached late-phase testing. Major barriers include viral dark matter, specimen and assay heterogeneity, disease-related confounding, limited external validation, and weak causal evidence. Standardized, mechanistically anchored, multi-kingdom studies are needed to establish clinical utility.
    Keywords:  anelloviruses; bacteriophages; colorectal cancer; gastrointestinal cancer; gut virome; metagenomics; oncogenic viruses; phage–bacteria interactions; translational oncology; viral biomarkers
    DOI:  https://doi.org/10.3390/v18101131
  74. PLoS Med. 2026 Oct;23(10): e1005140
       BACKGROUND: Human antibiotic use is widely believed to contribute to the evolution and maintenance of antimicrobial resistance (AMR) in bacterial pathogens. While antibiotic stewardship should thus discourage use in situations where AMR-related harms outweigh clinical benefit, evidence to inform this assessment of tradeoffs is lacking, most notably in low-resource settings where gaps in antibiotic access persist. Quantitative understanding of use-resistance relationships is thus necessary as countries navigate commitments from the 2024 UN General Assembly resolution to reduce AMR burden by 2030.
    METHODS AND FINDINGS: We used global surveillance data on AMR prevalence from 2000 to 2018 representing over 30 million bacterial isolates from 114 countries, along with antibiotic consumption estimates for each country and year, to estimate elasticity relationships between AMR and antibiotic exposure. Our analyses addressed 16 bacterial pathogens and antibiotic consumption across 7 drug classes, controlling for country-level health and development indicators via weighted regression models. Across pathogens, evidence that AMR is associated with population-level antibiotic exposure is strongest for Acinetobacter spp., Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. In a modeled counterfactual scenario, we estimate that 10% lower levels of antibiotic use, in comparison to current levels, across classes, would be associated with 38,000 (95% confidence interval: 36,000-41,000) fewer annual deaths attributable to AMR globally. Although substantial, this total represents only 0.50% of estimated bacterial disease mortality. In sub-Saharan Africa, where risk of death due to bacterial disease is greatest, the modeled avertible burden of AMR-attributable deaths comprises only 0.34% of bacterial disease mortality. Key limitations of the study include reliance on ecological relationships to infer modifiable burden, and under-representation of low-resource settings in surveillance data on antibiotic consumption and AMR.
    CONCLUSIONS: Our findings suggest near-term achievable reductions in AMR-attributable deaths may be modest relative to the persisting burden of bacterial disease mortality. These estimates should inform assessments of the potential benefits and harms of restrictive versus permissive antibiotic use paradigms in epidemiologically distinct settings.
    DOI:  https://doi.org/10.1371/journal.pmed.1005140
  75. Front Cell Infect Microbiol. 2026 ;16 1971575
      During perimenopause and postmenopause, changes in estrogen exposure may alter mucosal barriers, microbial ecosystems, and inflammatory responsiveness across the oral and genitourinary tracts. These stages differ in their hormonal patterns, and much of the available evidence comes from postmenopausal women or experimental models of estrogen deficiency. In the oral cavity, altered salivary function, gingival immunity, epithelial integrity, and alveolar bone metabolism may increase the inflammatory potential of established biofilms without generating a uniform menopause-associated microbial signature. When periodontitis develops, disruption of the gingival barrier can promote repeated exposure to microbial products, cytokine spillover, hepatic acute-phase responses, endothelial activation, and myeloid activation, thereby adding to systemic inflammatory burden. In parallel, hypoestrogenism can weaken vaginal, urethral, and bladder epithelial resilience, reduce Lactobacillus-associated colonization resistance, and impair tissue repair. The association between hypoestrogenism and recurrent urinary tract infection is better supported than corresponding associations with bacterial vaginosis or vulvovaginal candidiasis. Genitourinary syndrome of menopause may cause overlapping symptoms and coexist with infection. In this narrative review, we propose an estrogen-sensitive oral-systemic-genitourinary axis in which periodontal inflammation may amplify genitourinary susceptibility through systemic inflammatory signals and possibly through changes in intestinal and vaginal ecosystems. Hypoestrogenism may provide a permissive background, while local microbial or inflammatory challenges contribute to clinical disease. This proposed interaction does not require direct bacterial dissemination to the genitourinary tract. Evidence supporting the individual components is stronger than direct human evidence for the complete pathway, and a contribution from persistent myeloid reprogramming remains unproven. Longitudinal multisite studies integrating hormonal trajectories, periodontal status, systemic immune markers, and microbiologically confirmed genitourinary outcomes, together with combined periodontal and local estrogen interventions, are required to test this hypothesis in perimenopausal and postmenopausal women.
    Keywords:  genitourinary vulnerability; mucosal immunity; perimenopause; periodontal dysbiosis; recurrent UTI; systemic inflammation
    DOI:  https://doi.org/10.3389/fcimb.2026.1971575
  76. Pharmaceuticals (Basel). 2026 Oct 02. pii: 1567. [Epub ahead of print]19(10):
      Identifying bioactive compounds in traditional Chinese medicine (TCM) requires computational prioritization to be connected with chemical and pharmacological evidence. This structured narrative and critical review examines machine learning applications in compound prediction, formula-compatibility analysis, multi-omics integration, and drug development and repurposing. Molecular fingerprints, graph and sequence representations, knowledge graphs, and generative models are discussed in relation to their intended endpoints and validation conditions. Studies are classified along two independent dimensions: application scope, distinguishing direct TCM applications from natural-product studies and general drug-discovery methods, and validation level, ranging from computational prediction to chemical, experimental, and clinical evidence. Three case analyses illustrate a TCM-specific graph-learning platform with chemical confirmation, a downstream animal and metabolomics study without machine learning screening, and a proposed causal framework assembled from separate studies. Across these applications, machine learning supports candidate ranking and hypothesis generation, but predicted targets, attention weights, and multi-omics associations do not independently establish target engagement, formula synergy, or therapeutic efficacy. Major limitations include chemical-domain shift, inconsistent database provenance, data leakage, sparse negative results, and incomplete experimental follow-up. Reliable advancement requires scaffold-aware or external evaluation, explicit applicability domains and uncertainty, traceable data processing, and constituent-resolved intervention studies. A minimum reporting checklist consolidates these requirements, while route-specific assessment distinguishes synthetic accessibility from biosynthetic feasibility. Together, these considerations provide a basis for evaluating screening claims and designing reproducible workflows toward experimentally supported TCM compound discovery.
    Keywords:  bioactive compound screening; drug repurposing; generative molecular design; machine learning; molecular representation learning; multi-omics integration; network pharmacology; out-of-distribution generalization; traditional Chinese medicine
    DOI:  https://doi.org/10.3390/ph19101567
  77. Pak J Pharm Sci. 2027 Jan 01. 40(1): 76-84
       BACKGROUND: Pseudomonas aeruginosa is widely recognized as a ubiquitous, drug-resistant, biofilm-forming bacterium that produces numerous virulence factors and plays a prominent role in hospital-acquired infections.
    OBJECTIVES: This study aimed to determine the prevalence of multidrug resistance (MDR), biofilm formation and biofilm-associated genes among P. aeruginosa isolates recovered from burn wound infections.
    METHODS: A prospective cross-sectional observational study was conducted in which total of 176 burn wound samples were collected and processed for bacterial isolation. Identification of isolates was confirmed by polymerase chain reaction (PCR) targeting the oprL gene. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disc diffusion method. Biofilm-forming ability was assessed using the microtiter plate assay. Furthermore, PCR was used to detect biofilm-associated genes, including pelA, pelD, cupA, algD, pelF, pslA, pslB and pslD, in biofilm-producing isolates.
    RESULTS: Out of 176 burn wound samples, 74 (42%) were positive for P. aeruginosa, among which 58 isolates were identified as MDR while all isolates remained susceptible to polymyxin B. Biofilm formation was observed in all MDR isolates, with 13.79%, 44.82% and 41.37% categorized as weak, moderate and strong biofilm producers, respectively, whereas only a limited proportion of non-MDR isolates demonstrated biofilm-forming ability (P = 0.001). Among MDR biofilm-forming isolates, biofilm-associated genes such as pslA and algD were each detected in 96.55% of isolates while cupA were identified in 94.82% of isolates. Notably, cupA showed a statistically significant association with biofilm-forming intensity (P = 0.020), suggesting its potential role in enhanced biofilm establishment among MDR isolates.
    CONCLUSION: Overall, the high prevalence of multidrug-resistant, biofilm-forming P. aeruginosa isolates recovered from burn wounds is an important microbiological concern. The frequent coexistence of multidrug resistance and biofilm-forming capacity observed in this study suggests a possible association that may complicate infection management and emphasizes the importance of continuous surveillance and effective infection control strategies.
    Keywords:  Biofilms; Burns; Multidrug resistant; Pseudomonas aeruginosa; Wound Infection
    DOI:  https://doi.org/10.36721/PJPS/2026.40.16579.1